Aspects of migraine and patent foramen ovale in ischemic stroke by Lantz, Maria
 From the division of Neurology 
DEPARTMENT OF CLINICAL NEUROSCIENCE 
Karolinska Institutet, Stockholm, Sweden 
 
ASPECTS OF MIGRAINE 
AND PATENT FORAMEN 
OVALE IN ISCHEMIC 
STROKE 
Maria Lantz  
 
 
Stockholm 2017 
 
 
 
  
 
  
 All previously published papers were reproduced with permission from the publisher. 
© Maria Lantz, 2017 
ISBN 978-91-7676-623-1
 
     Published by Karolinska Institutet. Printed by E-print AB 
 
  
Aspects of migraine and patent foramen ovale in 
ischemic stroke 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Maria Lantz 
Principal Supervisor: 
Christina Sjöstrand, Associate Professor 
Karolinska Institutet 
Department of Clinical Neuroscience 
 
 
Co-supervisor(s): 
Konstantinos Kostulas, PhD 
Karolinska Institutet 
Department of Clinical Neuroscience 
  
Elisabet Waldenlind, Associate Professor  
Karolinska Institutet  
Department of Clinical Neuroscience 
  
Magnus Settergren, Associate Professor  
Karolinska Institutet  
Department of Medicine 
  
Karin Wirdefeldt, Associate Professor  
Karolinska Institutet  
Department of Medical Epidemiology and 
Biostatistics (MEB) 
 
 
 
 
 
 
 
 
 
 
 
Opponent: 
Simona Sacco, Associate Professor  
Università degli Studi dell'Aquila  
Department of Life, Health and Environmental 
Sciences  
 
Examination Board: 
Katharina Laurell, Associate Professor  
Umeå Universitet  
Department of Pharmacology and Clinical 
Neuroscience 
  
Per-Olof Hansson, Associate Professor  
Göteborgs Universitet  
Department of Medicine   
  
Magnus Kaijser, Associate Professor  
Karolinska Institutet  
Department of Medicine 
  
 
 
  
ABSTRACT 
Stroke is one of the main causes of death and disability worldwide, and only in Sweden 
approximately 25 000 individuals suffer from stroke each year. This thesis focuses on 
two common conditions; migraine and patent foramen ovale (PFO) and their role in 
stroke.  
 
Migraine is a common primary headache disorder, affecting approximately 11-13 % of 
the population with a 3:1 female preponderance. One third of the patients have an 
initial aura of neurological symptoms before the headache, and clinically migraine can 
be divided into migraine with and without aura. The pathophysiological mechanisms 
are highly complex, and involve cortical spreading depression (CSD) as the substrate 
for migraine aura, and activation of the trigeminovascular system causing the headache.  
 
PFO is an inborn anomaly, a remnant from the fetal circulation, that is prevalent in 
approximately 25 % of the population. PFO enables shunting of venous blood to the 
arterial circulation, bypassing the pulmonary system and enables paradoxial 
embolization. PFO is associated with ischemic stroke, as well as migraine with aura. 
The reason for the latter is unknown, but may relate to micro-embolisms through a PFO 
triggering migraine attacks.   
 
For decades, migraine has been suggested as a risk factor for stroke and cardiovascular 
disease. The risk seems to be mostly related to migraine with aura, female gender and 
young age. The reasons for this are still unknown and probably multifactorial. Different 
theories involve increased prevalence of cardiovascular risk factors among migraineurs, 
co-existence of other co-morbid conditions increasing the risk for stroke (i.e. PFO and 
cervical artery dissection), and association to endothelial dysfunction with subsequent 
hypercoagulability and decreased vascular reactivity. Migraine with aura may also be 
associated with a phenotype, leading to an increased susceptibility for CSD, and an 
increased sensitivity to cerebral ischemia. This thesis involves four different projects 
concerning PFO and migraine in relation to stroke. The projects are performed in stroke 
populations (Study I-III) and in a population-based twin sample (Study IV). 
 
In Study I, patients with ischemic stroke investigated with transesophageal 
echocardiography were included (N=117), and dichotomized depending on the co-
existence of a PFO. The prevalence of PFO was 11.9 %. Patients were analyzed 
regarding cardiovascular risk factors and allele frequency of 100 different genetic 
markers, previously associated with cerebrovascular disease. Four genetic markers, 
located in the Prothrombin-, Selectin E- and Apolipoprotein C III- genes, were 
significantly associated with PFO. The strongest association was for Prothrombin 
20210 G/A (p= 0.0049), which is a marker associated with increased risk of venous 
thromboembolism. There were no differences regarding risk factors in the two groups. 
 
In Study II, patients with a diagnosis of TIA, ischemic or hemorrhagic stroke, admitted 
to the stroke ward during a six-month period, were included (N=175). Prevalence of 
migraine was investigated using a structured questionnaire, and patients were analyzed 
regarding cardiovascular risk factors and clinical characteristics of their stroke, 
depending on co-existing migraine or not. The prevalence of migraine was 20 %, which 
  
is comparable to prevalence estimates in the general population. However, migraine 
with aura was more prevalent than expected (61 % of those with migraine). Migraine 
was associated with PFO. Most stroke patients had a favorable outcome after stroke 
and there was no difference in stroke severity depending on migraine status.  
 
In Study III, patients with cryptogenic stroke and PFO, planned for closure of their PFO 
(N=20) or on medical treatment only (N=7), were included. Patients were followed 
prospectively from baseline to six month after closure. Fifty percent of the patients had 
co-existing migraine, whereof the majority had migraine with aura (84.6 %). 
Endothelial dysfunction was assessed at baseline and after one day, one month and six 
months. A majority of patients had an impaired endothelial function at baseline, but 
there was no change after PFO closure. In a few patients, migraine frequency was 
impacted after closure with a distinct increase in migraine attacks after the procedure. 
At a second, long-time follow-up, the majority of patients were improved regarding 
frequency of migraine attacks.  
 
In Study IV, the risk for stroke related to migraine was investigated in a population 
from the Swedish Twin Registry (N=53 404). A diagnose of migraine with or without 
aura was identified through a symptom based algorithm. The twins were followed 
longitudinally for more than 10 years for the outcome of stroke, using data from 
national patient registries. There was no general increased risk for stroke associated 
with migraine, but twins with migraine with aura had a border-significant 27 % 
increased risk for stroke. Further analysis suggested that this could be impacted by 
familial factors. However, in comparison with previous studies, our results showed a 
considerably weaker association to stroke related to migraine.  
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1 BACKGROUND 
Stroke has a huge impact on disease burden worldwide, affecting millions of people 
each year. Even if there has been a decline in cardiovascular mortality in recent years, 
stroke is still one of the leading causes of death and disability (1, 2). In Sweden, each 
year approximately 25 000 individuals suffer from a stroke and 8 000 patients have a 
TIA. Of all stroke cases, approximately 25 % are recurrent events (3).  
 
This thesis focuses on two common conditions and their role in relation to stroke; 
migraine, which is a common primary headache disorder, and patent foramen ovale 
(PFO), an inborn cardiac anomaly. 
 
 
1.1 WHAT IS STROKE? 
Stroke is the collective name for ischemic and hemorrhagic stroke. The major part of 
all strokes (85 %) are ischemic, caused by the obstruction of a cerebral blood vessel, 
which leads to brain ischemia unless the blood flow is restored. Different 
pathophysiological mechanisms can lead to an ischemic stroke. It can arise due to a 
thrombus formed locally in the blood vessel, or from an embolus of a remote origin 
traveling with the blood stream to the sight of infarction. It can also be due to 
insufficient cerebral blood flow caused by hypoperfusion. The remaining 15 % of 
stroke cases are caused by rupture of a blood vessel in the brain or in the subarachnoid 
space (i.e. hemorrhagic stroke) (4). A TIA (transient ischemic attack) is an episode of 
focal neurological symptoms of presumed vascular origin; regressing completely within 
24 hours, without signs of ischemic injury (5).  
 
The mean age for having a stroke is approximately 75 years of age. Stroke is equally 
affecting men and women, however the mean age for stroke is lower in men than in 
women; 73.1 years for males compared to 77.9 years for females (3). Approximately 
25-30 % of the patients are under 65 years of age at stroke onset (6), and 10 % of 
admitted stroke patients are under 55 years of age (7).  
 
 
1.1.1 Etiology of Stroke 
Stroke is a heterogeneous disease that can be caused by a wide range of disorders; 
however, the most common causes for stroke are large artery atherosclerosis, small 
vessel occlusion and cardio-embolic stroke, the latter mainly due to atrial fibrillation. 
Other causes range from non-atherosclerotic disorders of the cerebral arteries, genetic 
disorders, abnormal coagulation, and infections and systemic disorders involving the 
cerebrovascular system (8). Ischemic stroke can be divided into different categories 
based on the probable underlying pathophysiological mechanism and stroke etiology. 
The TOAST system is the most widely used classification system; dividing patients 
into Large artery atherosclerosis (LAA), Small artery occlusion (SAO), Cardio-
embolism (CE), stroke of other determined etiology and stroke of undetermined 
etiology (9).  
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1.1.1.1 Risk factors of stroke 
Both genetic and environmental factors affect the risk for stroke. The incidence for 
stroke increases exponentially with age (6), and the risk doubles for every decade after 
55 years of age (10). Other important risk factors are conditions that predispose for 
atherosclerosis like smoking, hypertension, hyperlipidemia and diabetes mellitus. 
Cardiac disease like atrial fibrillation, recent myocardial infarction and valvular disease 
are important risk factors for cardio-embolic stroke.  
 
1.1.1.2 Endothelial dysfunction as a risk factor for stroke 
The innermost layer of the vessel wall consists of endothelial cells, which have vital 
biological functions. Endothelial cells produce a large number of substances that play a 
role in maintaining vascular tone, in thrombosis and homeostasis, as well as in 
inflammation and angiogenesis (11, 12). Important mediators in maintaining vascular 
tone are nitric oxide (NO) and prostacyclin, which have vasodilator capacity, and 
endothelin-1 (ET-1) which is a potent vasoconstrictor. In the healthy endothelium, ET-
1 and NO works inter-dependently in regulating vascular tone (13).  
 
Endothelial dysfunction (ED) is considered one of the first steps in the development of 
atherosclerosis. ED is characterized by a reduction in the bioavailability of vasodilators 
and an increase in endothelial-derived contracting factors. This leads to an impairment 
of endothelium-dependent vasodilatation. Another characteristic of ED is endothelial 
activation causing a pro-inflammatory and pro-thrombotic state. ED develops with 
increasing age and in the presence of risk factors for cardiovascular disease; such as 
smoking and hypertension. It is associated with the development of atherosclerosis and 
future cardiovascular disease (11, 14, 15). There are several biomarkers that may be 
used evaluating ED; ET-1, von Willebrand factor (vWf), homocysteine (Hcy), hs-CRP, 
endothelial progenitor cells (EPC) and endothelial microparticles are examples of 
biomarkers for ED (16-19). In the section below, biomarkers used in this thesis (Study 
III) are described. 
 
- ET-1 is mainly produced by endothelial cells, but also by smooth muscle cells 
and macrophages. ET-1 works as a potent vasoconstrictor by binding to 
receptors in vascular smooth muscle cells, but it also has pro-inflammatory 
effects. The plasma levels of ET-1 are, for example, affected by shear stress and 
pro-inflammatory cytokines (20). Higher concentrations of ET-1 have been 
shown to predict future cardiovascular events and also to predict mortality in 
patients with acute heart failure (21, 22) .  
 
- vWF is produced by endothelial cells and mega-karyocytes, but under normal 
conditions vWf is only produced by endothelial cells. vWf works pro-
coagulatory by increasing platelet aggregation, and it’s also a carrier protein for 
Factor VIII. It is released as a response to vessel injury, but elevated plasma 
levels of vWf have also been seen in patients with ischemic heart disease, 
diabetes mellitus and stroke (20, 23, 24).  
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- Hcy is a metabolite in cysteine and methionine metabolism, and high levels of 
Hcy have been associated with cardiovascular disease. High levels of Hcy leads 
to increased oxidative stress and reduced bioavailability of NO, and has also 
been associated with higher concentrations of ET-1 (25, 26).  
 
- CRP is a plasma-protein and a well-known marker of inflammation. It is an 
acute-phase protein, produced by the liver where the production is regulated by 
different cytokines. CRP affects the endothelium by downregulating the 
production of NO, and also by inducing the production of different adhesion 
molecules. Several studies have shown that hsCRP (high sensitive CRP) is an 
independent predictor of future cardiovascular disease (27, 28).  
  
1.1.1.3 Aspects of age in stroke etiology  
Age is an important aspect to consider in the work-up of a stroke patient. Younger and 
older patients differ; both regarding gender representation and etiological causes for 
stroke. Among younger stroke patients (<60 years); female gender is more common in 
the youngest patients (< 35 years of age), while there is a male dominance in middle-
aged individuals (29-31). Regarding etiology of stroke, major causes like atrial 
fibrillation, atherosclerosis or small vessel occlusion plays a crucial role in older 
patients, while these are less common in younger stroke patients (29, 32). Instead, in 
younger stroke patients, other determined etiologies for stroke, like cervical artery 
dissection (CAD), PFO or migraine, are more common. A large portion of younger 
stroke patients have an undetermined cause of stroke (29, 30). However, traditional risk 
factors, especially smoking, have been shown to be highly prevalent also in younger 
stroke cohorts (31), and even in young patients with stroke of unknown source, 
atherosclerosis is more prevalent compared to controls (33).  
 
1.1.1.4 Genetic aspects of stroke 
There are many different genetic traits that may increase the risk of stroke. Though 
rare, there are around 50 different monogenetic diseases increasing the risk of stroke. 
Of these, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) is one with particular interest in regards to migraine 
and stroke, since the phenotype of CADASIL often starts with migraine with aura, 
followed by early onset of stroke and dementia. CADASIL is caused by a mutation in 
the NOTCH-3, leading to sub-cortical infarctions (32, 34).  
 
Foremost, stroke is a polygenic disease, where different gene variants, each with a 
small individual effect, may increase the risk of stroke; either by affecting the 
likelihood of cardiovascular risk factors, or interacting with risk factors and 
environmental factors, increasing the risk of stroke. Through candidate-gene studies, 
and genome-wide association studies (GWAS), a large number of different single 
nucleotide polymorphisms (SNPs) have been found, affecting the risk for stroke. Many 
of these markers have been located in genes involved in inflammation, lipid 
metabolism, coagulation and hemostasis and the renin-angiotensin-aldosteron system 
(35, 36). Most genetic markers have been associated to a specific subtype of stroke 
etiology (37, 38).  
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1.1.2 Stroke of unknown origin 
After a standard diagnostic work-up, the cause of stroke cannot be found in 
approximately 20-25 % of all stroke. These are often referred to as cryptogenic stroke 
(CS). However, the term CS complies both of patients with an unknown source of 
stroke, but also of patients with multiple causes of stroke or un-complete diagnostic 
work-up (39), and in stroke centers using more extensive investigations the rate of CS 
is consequently lower. In comparison with stroke of other determined causes, CS are 
often less severe and have lower mortality rate (40). CS is more common in younger 
age groups (30, 39), and has often more similarities with cardio-embolic stroke than 
stroke of other etiologies. In studies of patients with CS, prolonged cardiac monitoring 
has shown transient atrial fibrillation on follow-up, in an additional 10-15 % of the 
patients (41, 42).  
 
In recent years, another concept has been proposed; embolic stroke of unknown origin 
(ESUS) (43). In comparison to the term cryptogenic stroke, ESUS is defined as non-
lacunar stroke of unknown origin and requires a complete work-up, ruling out other 
potential sources of stroke. Possible underlying mechanisms might be atrial fibrillation, 
PFO or aortic arch atherosclerosis (44). 
 
 
1.2 MIGRAINE 
Migraine is a common neurological disorder and consists of recurrent headache 
episodes with certain diagnostic criteria. Like stroke, migraine has a high impact on 
disease burden and is according to the WHO one of the major causes of disability 
worldwide (45, 46).  
 
 
1.2.1 Definition of migraine 
A diagnose of migraine relies on the clinical description of the recurrent headache 
attacks and is assigned according to criteria set by the International Headache Society 
(IHS). Many patients experience prodromal symptoms before the development of 
headache; such as fatigue, frequent yawning, feeling of sadness or cognitive 
dysfunction (47, 48), and 1/3 of the patients have an initial aura of neurological 
symptoms (49). Currently diagnostic criteria are defined in ICHD-III (International 
Criteria of Headache Disorders, third version) (50). Depending on the clinical 
description, migraine can be defined as different subtypes.  
 
1.2.1.1 Migraine without aura 
The typical migraine headache follows certain characteristics regarding duration of the 
headache, type of headache and associated symptoms. For a definite diagnosis, there 
must have been at least 5 recurrent episodes (Table 1). There are large differences in 
the clinical expression of migraine, regarding frequency and severity of the attacks, 
both within the individual patient as well as between patients. It has been reported that 
approximately 50 % of the patients have an impact on their daily activities, or are at bed 
rest during a migraine attack (51).  
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1.2.1.2 Migraine with aura 
A diagnose of migraine with aura is based on the description of the aura only (Table 1). 
The aura can consist of single or multiple neurological symptoms and the most 
common aura presentation is visual symptoms with flickering of light, zigzag lines or 
scotomas in the visual field. A migraine aura evolves gradually, and in the case of 
multiple symptoms these come after one another, where each symptom last between 5-
60 minutes. Headache usually evolves at the same time, or within one hour after the 
aura, but is not essential for diagnosis and approximately 5 % have recurrent migraine 
auras without subsequent headache (47, 50). One criteria for diagnosis, is the exclusion 
of TIA as a cause to the symptoms. In comparison, TIAs usually present with sudden 
onset of symptoms, compared with the gradual onset in a migraine aura. 
 
1.2.1.3 Probable migraine 
Patients fulfilling all but one criterion for a migraine diagnosis according to ICHD are 
categorized as probable migraine. Probable migraine follows the same epidemiological 
patterns as definite migraine and responds to migraine specific treatments (52, 53). 
 
 
Table 1. Diagnostic criteria of migraine headache according to ICHD-III 
 
Migraine without aura           
Criterion A: At least five attacks fulfilling criteria B-D   
Criterion B: Headache attacks lasting 4-72 h (untreated or unsuccessfully treated) 
Criterion C: Headache has at least two of the following four characteristics: 
  
1 Unilateral location, 2 Pulsating           
quality, 3 Moderate to severe intensity,           
4 Aggravation with physical activity.      
Criterion D: During headache, at least one of the following:   
  
1 Nausea/vomiting or     
  
2 Photophobia/phonophobia    
Criterion E: Not better accounted for by another ICHD-3 diagnosis  
 
Migraine with aura                 
Criterion A: At least two attacks fulfilling criteria B and C     
Criterion B: One or more of the following fully reversible aura symptoms;    
 
1 Visual, 2 Sensory, 3 Speech, 
4Motor, 5Brainstem, 6 Retinal.         
Criterion C: At least two of the following four characteristics;     
 
1At least one aura symptom spreads gradually over ≥5 min, and if  
two or more symptoms, they occur in succession.  
 
2Each aura symptom last 5-60 minutes. 
 
3At least one aura symptom is unilateral.     
 
4The aura is accompanied/followed by headache 
within 60 minutes.      
Criterion D: Not better accounted for by another diagnosis, and TIA has been excluded. 
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1.2.2 Migraine epidemiology 
Migraine affects approximately 11-13 % of the adult population (54, 55). The median 
age of onset is 20-25 years of age (54), and the prevalence of migraine increases with 
age, reaching a peak between 30-40 years of age, while onset after the age of 40 is rare 
(56, 57). Thus, migraine prevalence is lower in older age groups. The overall migraine 
prevalence is about the same in the western world, and large population-based trials 
have shown a stable prevalence over the last decades (49, 51, 56).  
 
The incidence and prevalence of migraine also varies with gender. In childhood, boys 
have an earlier peak incidence rate compared to girls, resulting in equal prevalence of 
migraine in boys and girls at young age. After puberty, the incidence increase more 
rapidly in females, and during the reproductive years’ prevalence of migraine is 2-3 
times more common in females. In older age groups, the differences between the sexes 
again diminishes (51, 57). Data from Danish twin studies suggest that the female 
preponderance may be less apparent in migraine with aura (58).  
 
 
1.2.3 Migraine pathophysiology 
Migraine is a neurovascular disorder and the pathophysiological mechanisms are very 
complex and still not completely understood. The migraine aura and the migraine 
headache have different underlying mechanisms. The pain derives from activation of 
the trigeminovascular system, with release of neurotransmitters, mainly Calcitonin 
Gene Related Peptide (CGRP). The trigeminovascular systems have afferent 
nociceptors innervating meninges and cerebral blood vessels. Upon activation, the 
release of CGRP, leads to a vasodilatory response and release of cytokines and 
inflammatory substances causing neurogenic inflammation. Also. Neurons in the 
brainstem and the thalamus are activated (47, 59, 60).  
    
1.2.3.1 Migraine aura 
The migraine aura is believed to be caused by cortical spreading depression (CSD) (61, 
62). CSD, first described by Lao in 1944 (63), is a wave of slow depolarizing activity 
spreading across the brain cortex and followed by an inhibition in neuronal activity. 
During CSD changes in the cerebral blood flow has been seen, with an initial increase 
followed by a longer lasting decrease in blood flow, moving along the cortex, however 
staying above the threshold for ischemic injury (64). Neuroimaging studies have shown 
that the decrease in regional blood flow normally starts in the occipital cortex (62), 
corresponding to the most common aura presentation of a visual scotoma. Data from 
animal studies suggests that CSD can be triggered by many factors, for example 
vasoactive substances like ET-1, but also by cerebral ischemia and micro emboli’s (65). 
An elevation in extra-cellular potassium has been describes as a critical event in 
inducing CSD (61).  The initiation of CSD is influenced by gender, where female sex 
hormones increase the susceptibility to evoke CSD. On the other hand several migraine 
prophylactic treatments have been shown to inhibit development of CSD (61). Data 
from animal experiments show that CSD can activate nociceptors within the 
trigeminovascular system, where activation seems to be initiated with a delay 
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corresponding to the time between migraine aura and the development of headache (62, 
66).  
 
1.2.3.2 Genetic aspects 
Migraine is a complex disease with both genetic and environmental factors being 
important for the clinical expression (62, 67). The genetic background of migraine has 
been investigated in several candidate gene- and GWAS, and a meta-analysis of 28 
GWAS studies found 12 different gene variants associated with migraine (68).There is 
also a strong familial aggregation in at least 50 % of migraine patients (67, 69), and 
studies of the heritability of migraine ranges between 34-57 % (70, 71).  
 
Also, there are monogenetic variants of migraine. Familial hemiplegic migraine (FHM) 
is a rare dominant autosomal inherited disorder causing migraine attacks with an initial 
aura including motor weakness (72). In FHM, there are four different forms caused by 
mutations in different ion channels. The mutations lead to an enhanced susceptibility to 
induce CSD, and transgenic mouse models of FHM has been valuable in the studies of 
different pathophysiological mechanisms in migraine (62).  
 
1.2.3.3 ED and hypercoagulability in migraine pathophysiology 
ED has been implied in migraine pathophysiology, both as a cause and a consequence 
of migraine headaches. Numerous studies have investigated vascular reactivity and 
biomarkers of endothelial activation in migraine, both ictally and in between of attacks. 
Plasma concentrations of vWf and ET-1 have been shown to be higher ictally in 
migraine attacks (73). Another study showed that migraineurs had a decreased number 
of circulating EPC, serving as a marker for endothelial repair capacity (74). 
Migraineurs have also been shown to have an altered arterial function with reduced 
dilatory response to shear stress, which was also seen in patients with migraine of 
recent onset (75). Whether ED is involved in migraine pathophysiology is still a matter 
of debate, and different studies have shown conflicting results, where some even 
showed an improved endothelial function in migraineurs (76, 77). There have also been 
conflicting results whether ED is limited to the cerebral circulation, as opposed to also 
involve the systemic circulation (78). However, some of the prophylactic treatments 
used in migraine have an effect on improving endothelial function, and recently also 
statin treatment, which is known to improve endothelial function, was shown to reduce 
the number of migraine days in a randomized double-blind study (79).  
 
As discussed previously, ED leads to a pro-coagulatory milieu, with increased levels of 
for example vWf, which induces platelet aggregation. The role of platelet activation in 
migraine has previously been extensively investigated, with conflicting results, 
showing both increased and decreased platelet activation during, and in between of 
migraine attacks. A state of hypercoagulability in female patients with migraine, may 
also be associated with elevated levels of estrogen, which is pro-coagulatory. The fact 
that micro embolisms may trigger CSD and thus cause migraine attacks, have also been 
lifted in support of the association between migraine and hypercoagulability (80, 81).  
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1.3 PATENT FORAMEN OVALE (PFO) 
Patent foramen ovale (PFO) is a common cardiac anomaly, and a normal part of the 
fetal circulation. The PFO is a tunnel or flap, caused by the unfused structures that 
builds the atrial septum. It allows right-to-left shunting of the blood, thus bypassing the 
pulmonary system. After birth the pulmonary blood flow increases, leading to a raised 
pressure of the left atria and the flap is then pressed toward the left septum wall. Over 
the first few months after birth this leads to a permanent closure of the PFO (82-84). 
However, in a large part of the population the PFO stays open. A PFO can be 
diagnosed by using cardiac ultrasound or transcranial ultrasound to detect a right-to left 
shunt at rest or valsalva. The golden standard is the use of contrast enhanced 
transesophageal echocardiography (TEE) (85, 86). PFO is sometimes associated with 
an atrial septal aneurysm (ASA), which consist of a bulging movement of the septum 
membrane of more than 10 mm (87).  
 
 
1.3.1 Epidemiology 
The prevalence of PFO has been investigated in both autopsy studies and clinical 
populations with estimates ranging from 15-40 % (77, 84, 88), and an equal prevalence 
in men and women. Autopsy studies suggest that the prevalence of PFO decreases with 
increasing age (89). The reason for the unsuccessful closure of PFO is unknown, 
however there are data suggesting that PFO might be a familial trait (90).   
 
 
1.3.2 PFO and possible pathophysiological mechanisms 
Usually, a PFO does not impact the normal physiological function of the heart. 
However, the finding of a PFO have been associated with a range of conditions; 
ischemic stroke and systemic embolism, obstructive sleep apnea syndrome (OSAS), 
migraine and decompression sickness (91-94). A PFO allows for shunting of 
deoxygenated blood from the right atrium to the left. This enables paradoxical 
embolism; i.e. clots formed on the venous side allows bypassing the lungs and instead 
reaching the arterial circulation. This mechanism has been implicated both in migraine 
and stroke pathophysiology, where the size of the clot could lead to either a migraine 
attack, or an ischemic stroke depending on the size (65). It’s also suggested that the 
presence of a PFO can induce transient arrhythmias due to atrial vulnerability (95) or in 
the combination of a PFO and ASA, promote formation of thrombi within the ASA 
(96).  
 
The shunting of blood also allows substances normally filtered in the pulmonary 
circulation, to reach the systemic circulation in higher concentrations (97, 98), which 
might explain the association with stroke and migraine. In OSAS, a PFO might 
exacerbate hypoxemia, and it is suggested that patients with OSAS and a PFO might 
get symptomatic at an earlier stage (93).  
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1.4 STROKE, MIGRAINE AND PFO – AN INTRIGUING CLINICAL TRIAD 
Stroke, migraine and PFO, are three clinical conditions with large diversities regarding 
epidemiology and clinical expression. Stroke is a devastating disease affecting mostly 
older individuals and a leading cause of death and disability. In contrast, migraine is 
considered a mainly benign disease, affecting people in childhood through early 
adulthood and midlife, and PFO is an inborn anomaly that in most cases are clinically 
silent. However, despite the diversity, during the last decades’ data from both clinical 
studies and animal experiments have implied that these conditions are related with one 
another.  
 
In the following sections, I will present the current knowledge of the associations 
between migraine and stroke, PFO and stroke and migraine and PFO respectively. As 
for stroke and migraine; migraine is a primary headache disorder and cannot be caused 
by stroke. However, as implied previously, brain ischemia and other neurovascular 
conditions can induce migraine-like headache attacks, which further complicate the 
associations between the three conditions (99).    
 
 
1.4.1 Migraine – association to stroke and cardiovascular disease 
Over the last decade’s numerous case-control studies and cohort studies have 
investigated the association between migraine and an increased risk of stroke, 
cardiovascular disease, and cardiovascular death (100-111). To this date, five meta-
analyses have been published analyzing migraine and its role in stroke and 
cardiovascular disease (112-116). A meta-analysis by Spector et al. in 2010, including 
studies of the association to ischemic stroke, yielded an approximately two-folded 
increased risk (114). In the most recent meta-analysis by Hu et al., analyzing the risk 
for total stroke, including only prospective cohort studies, the relative risk (RR) for 
overall stroke was lower with RR 1.55 (95% CI 1.38-1.75) for total stroke and RR 1.64 
(95 % CI 1.22-2.20) for ischemic stroke (115). For hemorrhagic stroke, results are more 
uncertain. There are studies indicating an increased risk (117, 118), but in the recent 
meta-analysis by Hu et al. there was no association to hemorrhagic stroke (115). 
Migraine has also been associated with an increased risk of white-matter lesions 
(WML) and silent infarcts (119-121), however recent data have shown conflicting 
results regarding this (122, 123). 
 
In many studies, the risk for stroke related to migraine, has been carried by the 
subgroup of patients with migraine with aura. There is also a stronger association with 
female gender, young age < 45 years of age, as well as smoking and the use of oral 
contraceptives (113, 124). In comparison, a prospective cohort study in men by Kurth 
et al, did not show an increased risk for ischemic stroke (125). Also in a population 
based study of older individuals by Monteith et al, there was no increased risk of stroke 
related to migraine (126). Further, data suggests that the risk for stroke is related to 
active migraine and the frequency of migraine attacks, where at least monthly attacks 
seem to further increase the risk (105, 127).  
 
To have a stroke at young age is still a rare event, and the absolute risk in migraineurs 
have been estimated to 1.8-4 additional strokes/10 000 women/ year (128) or 18 
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additional cardiovascular events/10 000 women with migraine with aura/year (109). 
There is also data suggesting that migraineurs often have stroke with good functional 
outcome (129). 
 
 
1.4.2 Proposed mechanisms to the migraine-stroke association 
If all migraineurs have an increased risk for stroke and the reason for this, is still a 
question of debate. Several hypotheses have been proposed, none being the sole 
probable mechanism between the migraine-stroke association. Most likely the cause is 
multi-factorial and may include both genetic and environmental factors, as well as 
relate to the pathophysiological mechanisms in migraine. 
 
1.4.2.1 Migraineous infarction – a rare cause of stroke 
Patients with migraine can suffer from a stroke in relation to a migraine attack, i.e. 
migraineous infarction. According to IHS criteria, a stroke can be diagnosed as a 
migraineous infarction if the patient has a previously known migraine with aura, and if 
the stroke is associated with a typical aura, with at least one symptom persisting for 
more than 60 minutes. Neuroimaging must show an ischemic lesion in a location 
corresponding to the aura, and the infarction must not be attributed to any other 
disorder (50). A migraineous infarction is a rare event; < 0.5-1% of all ischemic 
strokes. In a study of 2 000 consecutive stroke patients, only nine patients fulfilled 
criteria for migraineous infarction. However, in younger stroke patients migraineous 
infarctions are more common (130, 131). Data on the clinical description of these cases 
are scarce, however the most common presentation is a stroke in the posterior 
circulation, and it usually has a favorable outcome. Female gender is more common 
among patients with migraineous infarctions, corresponding to migraine being more 
prevalent among females (130, 132). 
 
1.4.2.2 Migraine and prevalence of cardiovascular risk factors 
Migraine has been associated with a wide range of co-morbid conditions, including 
many cardiovascular risk factors. Previous studies have found an increased risk of 
hypertension, current smoking and peripheral artery disease in patients with migraine 
(133-135). Further, patients with overall migraine, as well as migraine with aura only, 
have been associated with increased cholesterol levels (134, 136), and there is also an 
association between migraine and obesity (137). Active smoking has in several studies 
been strongly associated with an increased risk for stroke in migraineurs (126, 138). On 
the contrary, diabetes mellitus has in some studies shown a negative association with 
migraine (139). Further, several studies have investigated intima-media-thickness, a 
pre-clinical marker of atherosclerosis, in migraine, with conflicting results (140-142).  
 
However, regardless of the association with cardiovascular risk factors, it seems like 
the prevalence of these risk factors do not affect the risk for subsequent stroke. On the 
contrary, the risk for stroke has been highest in those with the lowest Framingham risk 
scores, indicating a non-atherosclerotic mechanism behind the migraine-stroke 
association (124, 138).  
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1.4.2.3 Association to co-morbid conditions increasing stroke risk 
Migraine has been associated with other conditions, that in turn are associated with 
ischemic stroke, especially in younger age groups. CAD, which is a common etiology 
for stroke in young patients, has been associated with migraine. In a meta-analysis of 
case-control studies migraine, irrespective of aura status, was associated with a two-
folded increased risk for CAD. Further data from larger observational- and prospective 
cohort studies, have shown that migraine are more common in stroke patients with 
CAD, compared to stroke patients of other etiologies. The reason for the association is 
not clear, but may relate to shared genetic risk markers, or ED (143-145).  
 
Migraine has also been associated to PFO, which enables cryptogenic embolism as a 
source of ischemic stroke. This will be further discussed in later sections. 
 
1.4.2.4 Genetic factors predisposing for ischemic ischemia? 
In recent years, another hypothesis has been proposed which suggests that migraine is 
associated with a phenotype of cerebral hyperexcitability, leading to an enhanced 
susceptibility to induce CSD, which in turn might increase the brain tissues sensitivity 
to ischemia (62, 146). Data supporting this hypothesis mainly comes from animal 
studies in mice expressing the gene for FHM, one of the monogenic disorders causing 
migraine.  
  
Both stroke and migraines are heterogeneous and complex diseases with genetic traits. 
In ischemic stroke, many different SNPs have been associated with an increased risk of 
stroke. Some of these have also been associated with migraine, for example in genes 
involved in vasodilatation and homocysteine metabolism (147-149). There are also 
monogenic disorders, like previously described CADASIL, with both ischemic stroke 
and migraine in the clinical expression. 
 
1.4.2.5 Association to ED and hyper-coagulability 
As discussed earlier, ED has been suggested to play a role in migraine 
pathophysiology, and it has been implied that this could explain the increased risk for 
stroke and cardiovascular disease related to migraine. Circulating endothelial 
progenitor cells, which are inversely correlated with risk for cardiovascular disease 
(150), have been found to be reduced in patients with migraine (74, 151). Other studies 
have indicated that migraineurs have reduced vascular reactivity, as well as increased 
levels of biomarkers associated with endothelial activation (76, 77, 152). However, 
studies are inconsistent, showing both impaired as well as unchanged and improved 
endothelial function in migraineurs. Overall, conducted studies are small and have been 
using different techniques making comparisons between studies difficult. 
 
1.4.2.6 Migraine specific treatment affecting the risk of stroke? 
Migraine specific treatment, i.e. triptans, are used by many patients as an acute 
treatment to abort a migraine attack. Triptans are 5-hydroxytryptamine (5-HT) - 
receptor agonists, and have vasoconstrictor properties. They are thus contraindicated in 
patients with uncontrolled hypertension and cardiovascular disease (60), and have been 
suggested to mediate the risk for stroke in migraineurs. However, several studies have 
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failed to show an association between triptan use and risk of stroke among migraineurs 
(107, 153).    
 
 
1.4.3 PFO and the risk of stroke 
The risk of stroke related to a PFO has previously been investigated in two population 
based studies of individuals without prior cardiovascular disease. Both in the NOMAS 
and the SPARC study, there were no independent association between PFO and an 
increased risk for ischemic stroke (154, 155). However, previous studies have shown 
that PFO is overrepresented in patients with CS compared to patients with stroke of 
known etiology. A PFO have been found in 40-56% of patients with CS, while only in 
4-18% of controls (96, 156-158). Studies examining the prevalence of PFO, ASA or the 
combination of the two, in stroke patients were analysed in a meta-analysis by Overell 
et al. in 2000. The results showed that the RR for stroke in a patient with PFO, 
regardless of age, was 1.83 compared to controls (95% confidence interval (CI), 1.25-
2.66). In younger patients (<55yrs) the RR was 3.10 (95% CI, 2.39-4.21), indicating a 
significant association with ischemic stroke in younger patients (159).  
 
The main hypothesis regarding pathophysiological mechanisms in PFO related 
ischemic stroke, is paradoxical embolism from the venous circulation due to a right to 
left shunt. Pro-thrombotic mutations, like prothrombin 20210 G/A and factor V 
Leyden, increasing the risk for venous thrombo-embolism, have been associated with 
an increased risk for stroke in patients with PFO (160), however the finding of a deep 
venous thrombosis preceding the stroke is not common (161), and other factors may 
influence the risk for stroke. Other theories suggest that the PFO may induce 
arrhythmias or promote thrombus formation when in combination with an ASA (95, 
96). Also, due to the shunt-hypothesis described previously; potentially harmful 
substances may reach the systemic circulation in higher concentrations, increasing the 
risk for stroke or other cardiovascular disease. For example, high levels of Hcy, which 
have been associated with ED, have been shown to decrease after PFO closure (17, 
162).  
 
 
1.4.4 Treatment of PFO after cryptogenic stroke 
There is a general agreement that there is no role for primary prevention of a PFO, 
either by closure of PFO or medical therapy. On the contrary, the best treatment for 
secondary prevention of PFO in relation to ischemic stroke, has been much debated for 
many years. As in all stroke care, anti-thrombotic treatment is administered in order to 
prevent recurrent strokes. A PFO can also be closed either by open surgery or by 
endovascular closure. The endovascular procedure is minimal invasive and though 
preferred over open surgery. It is generally accepted as a safe procedure, although 
complications occur; the most common being local hemorrhages at the puncture site. 
Other reported complications are atrial fibrillation and procedure related thrombosis 
(163). In Stockholm, the decision on best secondary prevention in ischemic stroke and 
PFO are decided on multi-disciplinary rounds at the Karolinska University Hospital. 
 
 
   13 
1.4.4.1 Anti-platelet therapy vs anti-coagulant therapy 
Both anti-platelet and anti-coagulant therapies are used in secondary prevention of PFO 
related ischemic stroke. Several studies have investigated the effectiveness of anti-
platelets vs. anti-coagulants. In the TAcTiCS-PFO study, pooling individual patient 
data from 12 different studies, there were no benefit of anti-coagulant over anti-platelet 
therapy. In clinical practice, anti-coagulants seem to be more widely used in patients 
with large shunts or associated ASA (164, 165).   
   
1.4.4.2 Medical therapy vs closure of PFO. 
Previous case-control studies reported a reduced risk for recurrent stroke in patients 
with CS and PFO, going through closure compared to medical treatment only (166, 
167). On the contrary, a prospective study, comparing medical therapy vs. closure in 
patients with CS and PFO under the age of 45, did not prove a significant benefit from 
closure over medical therapy, unless in those with large shunts or under 37 years of age 
(168). Until now, three randomized controlled trials (RCT) have been conducted; PC-
trial (169), RESPECT (170) and CLOSURE (171), while the REDUCE trial is still 
ongoing. All three published RCTs failed to show a significant risk-reduction for 
recurrent stroke by closure of the PFO, compared to medical therapy.  
 
In all studies, recurrent events were rare, and the studies were most likely 
underpowered. Shortly after publication of the RCTs, three meta-analyses pooling the 
data were published, also failing to show a significant benefit from PFO closure (172-
174). However, when stratified by device, one device (Amplatzer) showed significant 
benefit over medical therapy alone (174). A more recent analysis of pooled individual 
participant data, also controlling for age, gender and cardiovascular risk factors, 
showed a significant reduction of recurrent stroke with PFO closure compared to 
medical treatment only (175). Also, recently reported long term data (unpublished) 
from the RESPECT trial, have shown a significant risk reduction over time compared 
to medical therapy.  
 
To be able to better determine who will benefit from PFO closure, Kent et al has 
constructed the Risk of Paradoxial Embolism score (RoPE) (176). This is a 10-point 
score, which aims at identifying a stroke-related versus incidental PFO, in patients with 
CS. Clinical characteristics for a stroke related PFO are young age at stroke onset, 
cortical infarcts and absence of cardiovascular risk factors. Overall patients with high 
RoPE-score (high risk for stroke-related PFO) have been shown to have a low risk for 
recurrent strokes, approximately one percent per year while on medical therapy.  
 
 
1.4.5 PFO and migraine 
Several studies have shown an increased prevalence of PFO in patients with migraine 
with aura; 40-60 % of patients have a PFO compared to 25% in the general population 
(177). These data could not be confirmed in the population-based NOMAS study, 
although PFO was there detected by transthoracic echocardiography (TTE), which may 
explain the overall low prevalence. In another observational study, MA was only 
associated with the combination of PFO and ASA (178, 179). Vice versa, migraine 
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with aura is also more prevalent in patients with PFO; 15-50% compared to 4-5% in the 
general population (180). It is still unclear; whether this is a causal relationship or a 
coincidence. However, micro emboli can trigger CSD (65) and one hypothesis is that 
emboli’s through the PFO can trigger CSD and cause a migraine attack. Also, as 
mentioned previously, the shunting hypotheses suggests that a PFO may lead to higher 
levels of vasoactive substances, normally degraded in the lungs, that can function as a 
trigger for inducing a migraine attack.  
 
Observational data on the effect of migraine after PFO closure have shown both a 
reduction, as well as new onset of migraine headache, and a temporary increase in 
migraine attacks after closure of a PFO. In a meta-analysis of observational studies, 
reporting migraine frequency after PFO closure in patients having the procedure due to 
stroke prophylaxis, the majority of patients had an improvement in migraine frequency 
after closure. This was especially noticed in those with migraine with aura, however 
included studies were mainly small and uncontrolled (181-183). The majority of stroke 
patients are also on secondary prevention treatment with both statins and anti-
thrombotic treatment, which both have been shown to have a prophylactic effect on 
migraine headaches (79, 184), making it hard to draw any conclusions.  
 
Previous studies in non-stroke migraine patients have investigated whether closure of a 
PFO can reduce migraine attacks. Non-randomized studies in patients with overall 
migraine and PFO, as well as those with large shunts indicating a high risk for 
paradoxial embolism, have shown improvement in migraine after closure of a PFO 
(183, 185). Two randomized trials have though failed to show a significant benefit on 
migraine from PFO closure. The MIST trial was a double-blind, sham-controlled study, 
evaluating the effect of PFO closure on patients with migraine with aura, with a 
primary endpoint of cessation of migraine. Patients were followed for six month after 
PFO closure. The study did not obtain its primary endpoint, however a post hoc 
analysis, excluding outliers who stood for 20 % of the headache days, showed a 
significant reduction in headache days compared to the sham group. Recently, the 
PRIMA trial, recruiting patients with migraine with aura, also failed to prove its 
primary endpoint of reduction in headache days (186, 187). There is currently no place 
for closure of a PFO in the treatment of migraine headaches. 
 
 
1.4.6 Clinical aspects of migraine in relation to stroke 
In clinical practice, we often come across patients with migraine and migraine-like 
features in relation to acute stroke, and it was these patients that initially sparked my 
interest to work within the field of migraine and stroke. In some of these patients a PFO 
has been a possible cause for the stroke, in others no cause has been found and the 
migraine-like features of the stroke cases may have been related to ischemia-induced 
CSD. We have previously described the clinical course of some of these cases, 
published in Acta Neurologica Scandinavia (188). In our clinical practice, we have also 
seen what might happen with frequency and clinical expression of migraine attacks 
after stroke onset, as well as after closure of PFO; both with temporary worsening and 
improvement of migraine attacks. 
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2 AIMS 
The overall purpose of this thesis project was to explore different aspects of migraine 
and PFO in relation to stroke, especially ischemic stroke. 
 
The specific aims of the thesis and its different studies were the following: 
 
▪ To investigate the frequency of migraine and PFO in a stroke population, in 
order to explore if cardiovascular risk factors were increasing the risk of stroke 
related to migraine or PFO (Study I and II).  
 
▪ To explore if conventional, or new risk factors could be used in assessing the 
risk for recurrent stroke, in stroke patients with co-existing migraine or PFO 
(Study I and III).  
 
▪ To investigate endothelial function in cryptogenic stroke patients with PFO, and 
to explore whether endothelial function was altered by closure of the PFO, and 
if any change would be related to a change in migraine frequency (Study III). 
 
▪ To investigate if migraineurs in a Swedish population had an increased risk for 
stroke, and if such a risk could be explained by familial factors (Study IV). 
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3 MATHERIAL AND METHODS 
 
3.1 PATIENT POPULATIONS 
The data used in this thesis derives from patient populations identified during clinical 
work performed in the stroke ward or at the out-patient clinic at the Karolinska 
University Hospital in Huddinge (Study II and III), previously collected material from 
the South Stockholm Ischemic Stroke Study (SSISS) (Study I), as well as register-
based data from the Swedish Twin Registry (Study IV). The catchment area for the 
stroke ward at Karolinska University Hospital covers the southern suburbs of 
Stockholm. In the out-patient clinic, patients come for follow-up after stroke care at the 
Hospital. However, during the recruitment period of participants for Study III, patients 
with CS and PFO were referred to the Karolinska University Hospital from the whole 
Stockholm area, due to the recruitment of a clinical study.  
 
All studies were approved by the Regional Board of Ethics. In Study II and III, all 
patients gave their written informed consent for participation. 
 
 
3.1.1 Study I 
Study I is a post-hoc analysis of a previous material, collected by co-supervisor Dr. 
Konstantinos Kostulas. SSISS was a genetic epidemiology study, that prospectively 
recruited patients with ischemic stroke or TIA attending the stroke ward, or out-patient 
clinic at the Karolinska University Hospital, during the period 1996-2002 (N=928). 
Controls were residing in the south Stockholm area and were sampled from blood 
donors and healthy individuals recruited by the Department of Clinical Chemistry at the 
Karolinska University Hospital (N=602). In the post-hoc analysis, patients investigated 
with trans esophageal echocardiography (TEE) as part of their stroke investigation were 
included (N=117), and dichotomized depending on co-existence of PFO.  
 
 
3.1.2 Study II 
In Study II, individuals eligible for participation, were patients with TIA and ischemic 
or haemorrhagic stroke, admitted to the stroke ward during a six-month period in 2009 
between May 1:st and October 30:th (N=276). Forty-seven patients were either dead or 
severely demented, at the time of the mailed questionnaire, and were thus not able to 
participate in the study. Information regarding the study and a questionnaire on 
recurrent headache episodes were mailed to the remaining patients (N=229). One 
reminder was sent per mail to non-responders. The response frequency was 76.4 %, 
resulting in inclusion of 175 patients in the final analysis, divided regarding exposure to 
life-time migraine headaches.    
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3.1.3 Study III 
Starting in 2009, there has been a collaboration between the departments of Neurology 
and Cardiology at Karolinska University Hospital, regarding patients with ischemic 
stroke and PFO. This was started as a response to participation as clinical investigators 
in the REDUCE study. In REDUCE, patients 18-60 years old, with a CS within the last 
six months, were randomized to closure plus anti-platelet treatment or antiplatelet 
treatment only, in a 2:1 ratio. The study was closed for recruitment in February 2015 
(Clinical trial, NCT 00738894). During the recruitment for REDUCE, patients deemed 
appropriate for participation, were called for a screening visit at the out-patient clinic at 
the Karolinska University Hospital. In Study III, patients screened for the REDUCE 
study were recruited in two different phases; May 2011 - February 2013 and February 
2014 - November 2014. In all 26 individual patients were recruited; 20 patients going 
through closure of the PFO and 7 controls. One patient started as a control, but had his 
PFO closed after six months, due to a recurrent ischemic event. All but three patients 
were randomized to their assigned treatment, while the remaining three were closed 
outside of the study.  
 
 
3.1.4 Study IV 
In Study IV, a large population-based sample from the Swedish Twin Registry (STR) 
was used. STR was founded in the 1950s in order to study the importance of smoking 
and alcohol on cancer and cardiovascular disease. It now comprises of all twins born in 
Sweden since 1886. Zygosity is assigned using questions on within-pair similarities in 
appearance during childhood. STR is updated on a regular basis regarding current 
addresses and is also cross-linked to national patient registries and the cause-of-death 
registry. Over the years, additional data have been collected from different cohorts 
within the STR (189). In Study IV, twin populations from the SALT and STAGE 
studies were used. 
 
3.1.4.1 SALT-Screening across the life-time study 
The study was initiated in 1998 and consisted of a telephone interview, screening for 
the most common complex diseases, as well as collecting data on environmental and 
socio-economic factors. The eligible population were twins born before 1958 and living 
in Sweden at the start of the study. Over 44 000 twins responded, and it was completed 
in 2002 (190). 
 
3.1.4.2 The SALT headache study 
In 2004, PhD-student Dan Svensson wrote his thesis on the genetic influence on 
primary headache disorders using data from STR (191). The SALT headache study 
comprised of twins from SALT, born 1926-1958. The questions were mapping onto 
diagnostic criteria for primary headaches; migraine with and without aura, tension-type 
headache and cluster headache. In our analyses the population from SALT consist of 
31 105 twins. 
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3.1.4.3 STAGE – The Study of Twin Adults: Genes and Environment 
The study was initiated in 2005 and consisted of a web based interview with similar 
questions as in SALT, regarding common complex diseases and environmental and 
socio-economic factors. All twins born 1959-1985 were contacted with an invitation 
letter and provided with a personal login. Non-responders were reminded and 
eventually offered to complete the survey by phone (190). In our analyses, 22 433 twins 
from STAGE were included.  
 
3.1.4.4 The merged twin cohort 
In Study IV, populations from SALT and STAGE, who answered the headache 
questions were merged into one cohort (N= 53 538). Individuals were excluded if 
information on date of study entry was missing, or if a diagnosis of stroke was found in 
national patient registers, prior to the start of follow-up. In total, 53 404 individuals 
were included in the final cohort (Figure 1). One third (30.2 %) of the twins were 
monozygotic, while 67.9 % were dizygotic. In 2 % of the twins, zygosity was 
unknown. Of included participants, 38 908 twins were parts of a complete twin pair. 
 
 
Figure 1. Study population in Study IV. 
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3.2 METHODS 
 
3.2.1 Diagnosing migraine from questionnaires 
3.2.1.1 Clinical studies 
In Study II and III, a questionnaire was used to identify patients with migraine 
according to ICHD-II.  The questionnaire had previously been validated to identify 
individuals with primary headaches (192). It consisted of questions regarding the 
diagnostic criteria for migraine and its subtypes. Patients with migraine with aura, 
migraine without aura and probable migraine were identified. In the statistical analysis, 
patients with co-existing migraine was analyzed disregarding of migraine subtype. The 
questionnaire is shown in Appendix 8.2.   
 
3.2.1.2 Twin studies 
The questionnaires in SALT and STAGE included questions of recurrent headache 
episodes and their characteristics. The first question singled out whether individuals 
have, or had had, recurrent headache episodes not caused by infection or other evident 
cause. Thereafter, additional questions covered characteristics of headache episodes 
according to ICHD-III criteria for migraine with and without aura. An algorithm was 
constructed to identify cases of migraine with or without aura, as well as probable 
migraine (Figure 2). The questions in SALT and STAGE were similar, though not 
identical. In STAGE a question on duration of headache was lacking, and therefore 
only a diagnosis of migraine with aura and/or probable migraine could be assigned, 
while for SALT all three diagnosis could be assigned. Diagnoses were overlapping, 
with twins fulfilling only one or multiple of the diagnoses. The statistical analyses were 
made according to the following constructed groups: 
 
 
• Any migraine – twin fulfilling criteria for either type of migraine 
 
• Migraine with aura – all twins fulfilling migraine with aura 
 
• Non-aura migraineous headache – Twins with migraine without aura or 
probable migraine, without co-existing migraine with aura 
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Figure 2. Algorithm used for assignment of migraine diagnosis in Study IV according 
to ICHD-III.  
 
 
 
 
  Yes 
                                     
 
 
 
            
 
                           Yes 
 
 
                         
 
 
 
 
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*visual disturbance such as flickering of light, zigzag lines moving in the visual field. 
 
 
 
 
 
Criterium A:                     
Recurrent headache attacks? 
Criterium B:                           
Duration of headache between 4 
hours and 3 days? 
Criterium C:                                       
2 out of 4 pain characteristics;                           
– moderate-severe pain intensity?     
– pounding headache?                                    
– unilateral headache?                                   
– worsening with physical activity? 
Criterium D:                                     
1 out of 2 associated symptoms;         
– Nausea/vomiting?                            
– Light-/sound sensitive? 
Fulfilling 2 out of 3 
criterium B-D? 
Probable migraine 
 
Migraine without aura 
 
Criterium migraine aura:     
– Visual aura* symptoms 
before start of headache?            
–Visual aura lasting for 
more than five minutes? 
Migraine with aura 
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3.2.2 Diagnostics and characteristics of cerebrovascular events 
3.2.2.1 Clinical studies 
In Study I-III, patient populations were previously sampled, or collected during clinical 
work at the Department of Neurology. All included patients had a diagnosis of TIA 
(ICD G45.1-G45.9), ischemic stroke (I63.1-I63.9) or hemorrhagic stroke (I61.0-I61.9), 
and we had access to medical records to verify the diagnosis if needed. 
 
3.2.2.2 Population based twin study 
In Study IV, a diagnosis of stroke was identified using the national patient register 
(NPR) and cause-of-death register (CDR) (193). NPR register diagnoses from hospital 
discharges and from outpatient visits at hospital-based clinics (194). Each record 
includes primary and secondary diagnoses. CDR contains diagnoses of causes of death; 
both major and contributory causes. Diagnoses are coded according to ICD-10 since 
1998. We identified all first-time diagnosis of stroke from study entry until 2014-12-31 
in these registries, using ICD-10 codes for cerebral ischemia (I63.0-I63.9 and G 46.0-
G46.8) and intracerebral bleeding (I61.0-I61.9). We had however no access to medical 
records and we were not able to assure the correctness of the diagnosis. We chose not 
to have TIA as an endpoint. 
  
3.2.2.3 Clinical description of stroke patients 
In Study I-III, all patients underwent relevant investigations as part of routine stroke 
care; brain imaging, routine blood tests, ultrasound or radiological examinations of the 
vessels and cardiology work-up, as judged relevant to the stroke physician. In Study I, 
stroke etiology had been characterized according to TOAST in all patients, as part of 
the original study. In Study II and III, clinical description, radiological features of the 
stroke and diagnostic workup were reviewed. In Study II and III, stroke severity at 
stroke onset and at follow-up, was assessed using National Institute of Health Stroke 
Scale (NIHSS) and Modified Rankin Scale (mRS). These are common stroke scales 
used to assess stroke severity and functional dependency after stroke. NIHSS are shown 
in appendix 8.1 and mRS are shown below (Table 2). 
 
Table 2. Modified Rankin Scale (mRS) 
 
Modified 
Rankin Scale 
(mRS) 
 
0 No symptoms 
1 No functional disability despite symptoms. 
2 Slight disability, cannot perform all previous activities. 
3 Moderate disability, but able to walk without assistance. 
4 Moderate to severe disability, cannot walk without assistance, 
and requires help in attending bodily needs. 
5 Severe disability, requires constant nursing and attention. 
6 Death 
 
 22 
3.2.3 Risk factors for cardiovascular disease 
3.2.3.1 Traditional cardiovascular risk factors 
Prevalence of common cardiovascular risk factors are presented in all studies. In Study 
I, definition of risk factors had been pre-defined in SSISS. In general, data were taken 
from medical history at stroke onset and from medical records regarding treatment with 
anti-hypertensive or hyperlipidemic drugs. In Study II and III similar methods were 
used for definition of risk factors; depending on the medical history from the patient at 
stroke onset, previous diagnosis in medical records, and the use of anti-hypertensive or 
hyperlipidemic drugs prior to stroke onset.  
 
In Study IV, the questionnaires in STAGE and SALT were used to identify risk factors. 
Both studies screened for the prevalence of common complex diseases including 
cardiovascular risk factors such as hypertension and diabetes mellitus, using simple yes 
or no questions. We also recorded smoking habits and calculated BMI from data on 
length and weight. A diagnose of atrial fibrillation was taken from NPR (ICD-10 I48.0-
I48.9). 
 
3.2.3.2 Genetic markers associated with ischemic stroke. 
In SSISS, genotyping was performed using Multiplex polymerase chain reaction 
studies and linear immobilized probe assays. The method has been described in the 
original study (195). The selected 100 SNPs had been shown to be associated with the 
development of atherosclerosis, including lipid metabolism, inflammation, thrombosis 
and hemostasis and platelet function. A list of the different markers is shown in 
Appendix 8.4. In Study II, allele frequency for all the different SNPs were calculated 
and compared between groups.   
 
 
3.2.4 Assessment of endothelial function 
ED has been discussed previously and involve impaired vascular reactivity and 
endothelial activation. Endothelial function can thus be assessed by measuring either 
vascular reactivity as a response to shear stress, or concentrations of biomarkers 
associated with endothelial activation. Evaluation of vascular reactivity can be done 
using different techniques; flow-mediated dilatation of the brachial artery (FMD) or by 
reactive hyperemia peripheral artery tonometry using a finger plethysmograph, and 
there is a wide array of different biomarkers that can be used to evaluate endothelial 
activation (20).  
 
In Study III, vascular reactivity and selected biomarkers were investigated at baseline 
(day before the closure procedure), the day after closure, one and six months after 
closure. The control patients were followed with the same intervals.  
 
3.2.4.1 Endo-PAT 2000® 
In Study III, Endo-PAT 2000® (Itamar Medical) was used to assess endothelial 
function. Endo-PAT 2000® is a non-invasive method estimating endothelial function. 
Its major advantage compared to FMD is that it is more simple and operator-
independent. Studies have shown that Endo-PAT 2000® and FMD are comparable in 
predicting the presence of coronary artery disease (196). Endo-PAT 2000® has also 
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been proven to have good reproducibility (197). Figure 5 shows the device, including 
the set-up with the patient. 
 
 
Figure 3. The Endo-PAT 2000® device, and set-up with the patient. (Published with 
permission of Itamar Medical). 
 
 
                         
 
 
 
The Endo-PAT 2000® measures pulse wave amplitude in the fingertip at baseline and 
as a response to shear stress. The changes in amplitude are used to calculate a reactive 
hyperemia index (RHI), showing the capacity to react with dilatation to shear stress. 
This in turn, corresponds with vascular endothelial function (Figure 6). The patients 
other arm serve as an internal control. Vascular reactivity is affected by many factors, 
for example temperature, time of day, smoking and coffee intake. The test was 
therefore taken in the morning after a fasting period (preferably overnight, but a 
minimum of 4 hours) and in a temperature controlled room. A RHI <1.67 correlates to 
ED and has been proven to predict future cardiovascular events (198, 199).  
 
 
Figure 4. The Reactive Hyperemia Index (RHI). Normal vascular response to shear 
stress (left), as opposed to ED (right). Published with permission from Itamar Medical. 
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3.2.4.2 Biomarkers of ED  
In Study III, venous blood was collected in serum- and EDTA-tubes and were either 
sent to the University laboratory at the Karolinska University Hospital, or stored in 
freezer awaiting further analyses. Blood samples were taken in the morning with 
patients fasting for a minimum of four hours. 
 
Concentration of ET-1was analysed with ELISA technique, performed by a laboratory 
assistant at the Department of Cardiology. The Kit QuantiGlo® from R&D systems was 
used, and the concentration was presented in pg/ml. Levels of hs-CRP, vWf and Hcy 
were analysed at the University Laboratory using standardized methods.  
 
 
3.3 STATISTICAL ANALYSIS 
Baseline characteristics were presented as percentages for categorical variables. 
Continuous variables were presented as means with +/- SD (Study I-II, IV), or as 
median with inter quartile range (IQR) (Study III) depending on the distribution of data. 
 
In Study I and II, Chi-Square or Fishers exact test was used to compare distribution of 
cardiovascular risk factors between stroke patients with or without co-existing PFO 
(Study I) or migraine (Study II). Fisher’s exact test was also used to estimate odds 
ratios for the association between the different SNPs and stroke (Study I).  
 
In Study III, repeated measures one-way ANOVA or Friedman’s test (non-parametric 
test) was used to evaluate whether there was a significant change of endothelial 
function over time after PFO-closure. For comparison of baseline values of RHI or 
biomarkers of endothelial activation, between closure patients and controls, non-
parametric test of Mann-Whitney or unpaired t-test was used. For comparison of RHI at 
baseline and after one day, Wilcoxon Signed Rank Test was used. 
 
In Study IV, Cox proportional hazards model with attained age as underlying time scale 
was used to estimate hazard ratios (HR) with 95 % confidence intervals. Assessments 
were made for any migraine, migraine with aura, and non-aura migraineous headache 
and the outcome of total stroke, ischemic stroke and hemorrhagic stroke. In order to 
adjust for dependence between observations in the twin data, a robust sandwich 
estimator was used. The model was initially adjusted for gender and age, which were 
considered true confounding factors, affecting both the risk of having migraine attacks 
and subsequent stroke. In a second step, the model was adjusted for established 
cardiovascular risk factors that could serve as a mediator, increasing the likelihood of 
stroke. With the use of an interaction term, separate analyses were made for women and 
men, as well as attained age of 50 years or older. Within-pair analysis was made to 
control for familial confounding factors in twins with migraine with aura. 
 
In all studies the significance level was set to p<0.05. The statistical software used was 
Graph Pad Instat Software (version 3.06) (Study I-II), Graph Pad Prism (Version 6.07) 
(Study III), SAS version 9.4 (Study IV) and STATA version 14.1 (Study IV). 
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4 RESULTS 
 
4.1 PREVALENCE OF MIGRAINE AND PFO IN STUDY POPULATIONS 
4.1.1.1 Age- and gender distribution in study populations 
Prevalence of PFO was investigated in Study I and II, and prevalence of migraine in 
Study II-IV. The prevalence of migraine is affected by the gender- and age distribution 
of the populations, which have to be accounted for when interpreting the data. Mean 
age and distribution of female gender in Studies II-IV are shown in Table 3.  
 
Table 3. Mean age and gender distribution of populations in Study I-IV. 
 
 Mean age (SD) Female gender 
Study I 59.0 (53-65) * 64.5 % 
Study II 69.3 (13.0) 46.3 % 
Study III 45.4 (8.5) 50 % 
Study IV (all) 45.3 (11.9) 54.3 % 
Study IV (SALT) 53.7 (5.8) 52.6 % 
Study IV (STAGE) 33.7 (7.7) 56.6 % 
*Non-normal distribution of data. Age presented as median with IQR. 
 
 
4.1.1.2 Migraine prevalence 
Figure 5 shows lifetime prevalence of any migraine headache, migraine with aura and 
non-aura migraine headache in Study II-IV. In Study II, 20.1 % had migraine, of which 
61.1 % had migraine with aura. Nine percent reported active migraine. In Study III, 
migraine prevalence was 50 %, of which 84.6 % had migraine with aura.  Migraine 
prevalence in Study IV was 16.2 %, of which 41.1 % had migraine with aura. The 
younger population in STAGE had higher migraine prevalence compared to SALT 
(19.5 % vs. 13.7 %) and the subtype of migraine with aura was more common among 
migraineurs in STAGE compared to SALT (49.0 % vs. 33.1 %). In the studies, the 
prevalence of migraine in females ranged between 27.2 % and 61.5 %, while in men 
prevalence ranged between 14.9 % and 38.5 %. 
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Figure 5. Lifetime prevalence of migraine headache in Study II-IV 
 
 
 
 
 
 
4.1.1.3 PFO prevalence 
Prevalence of PFO was investigated in Study I and II, but the method for identifying 
PFO varied between studies. In Study I, the population consisted of a subgroup of the 
initial SSISS population, examined with TEE as part of the routine stroke work-up. 
TEE as investigation method is mainly used in younger stroke patients, and only 12.6 
% of the initial SSISS population was included in Study I. Mean age of the patients 
were 58.5 years old. In Study II, mean age of study participants were 69.3 years, and 
61.1 % of the cohort (N=107) were examined with echocardiography as part of stroke 
investigation. Of these only 26.2 % were examined with TEE, while the majority was 
examined with TTE. The prevalence of PFO was similar in the two groups; 11.9 % in 
Study I and 11.2 % in Study II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,0% 10,0% 20,0% 30,0% 40,0% 50,0% 60,0%
Study II (N=175)
Study III (N=26)
Study IV-all (N= 53 404)
Study IV - SALT (N=31 038)
Study IV- STAGE (N=22366)
Any migraine headache Non-aura migraine Migraine with aura
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4.2 CARDIOVASCULAR RISK FACTORS CHARACTERISTICS OF 
STROKE 
 
4.2.1 Cardiovascular risk factors in stroke populations 
The population in Study I-II consisted of mixed stroke populations of different 
etiology, and presence of cardiovascular risk factors (smoking, hypertension, 
hyperlipidemia, diabetes mellitus and previous cardiovascular disease) were 
investigated in both studies, and analyzed in relation to co-existence of either PFO 
(Study I) or migraine (Study II). Data on peripheral artery disease were available in 
Study I and BMI in Study II. In both cohorts, traditional risk factors, especially 
smoking and hypertension, were highly prevalent (Table 4).  
 
Table 4. Prevalence of common cardiovascular risk factors in Study I and II 
 
 
  
Study I (N=117) 
% (n) 
Study II (N=175) 
% (n)  
Ever smoking 50.4 (59)        63.4 (111) 
Hypertension 41.9 (49)        68.6 (120) 
Hyperlipidemia 21.4 (25) 38.3 (67)  
Diabetes 12.8 (15) 19.4 (34)  
Atrial fibrillation 12.8 (15) 24.6 (43)  
Previous AMI*1 4.3 (5) 19.4 (34)  
Previous CVD*2 18.8 (22) 21.1 (37)  
BMI*3 - 25.6 (23.3-28.7)  
PAD*4 3.4 (4) -  
*1 AMI Acute Myocardial Infarction 
*2 CVD Cerebrovascular Disease 
*3 BMI presented as median with IQR 
*4 PAD Peripheral Artery Disease 
   
 
In Study I, mean age was similar in patients with and without co-existing PFO and 
there was no significant difference in risk factors between the groups, although 
hypertension was less common in patients with co-existing PFO (21.4 % vs. 44.7 %).  
 
In Study II, patients with co-existing migraine were significantly younger compared to 
those without migraine; mean age 63.4 years vs. 70.9 years (p=0.007). Co-existing PFO 
was associated with migraine (31.6 % vs. 6.8 %, p=0.007), and atrial fibrillation was 
less common in stroke patients with migraine (11.1 % vs. 28.1 %, p= 0.049). Otherwise 
there were no significant differences between the groups.    
 
In Study III, all patients were considered cryptogenic, and the majority were thus 
lacking cardiovascular risk factors, although a substantial part of the patients were 
previous smokers (38.5 %). Mean RoPE-score was high; 7.5 out of 10 possible.  
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4.2.2 Genetic risk markers in patients with stroke and PFO 
In Study I, allele frequency of 100 different SNPs was investigated in stroke patients 
with PFO compared to those without PFO, and to healthy controls.  Four SNPs were 
significantly associated to stroke patients with co-existing PFO (Table 5). These were 
located in Apolipoprotein CIII, prothrombin and Selectin E, where the strongest 
association was found for Prothrombin 20210 G/A (p=0.005). All four SNPs, and one 
additional SNP in Paraoxonase 1 were also significant compared to healthy controls 
(Table 6). 
 
Table 5. Frequency of minor allele, and Odds Ratio (OR) with 95% CI, in stroke 
patients with and without co-existing PFO.   
 
Gene Polymorphism Minor Frequency Frequency P OR 95 % CI 
   Allell (PFO+) (PFO-)    
Selektin E leu554phe(C/T) T 0.125 0.027 0.050 5.17 1.15-23.21 
Prothrombin 20210 G/A A 0.125 0.005 0.005 26.43 2.63-265.80 
Apolipoprot CIII -641C/A A 0.591 0.343 0.037 2.77 1.12-6.87 
Apolipoprot CIII -455T/C C 0.591 0.324 0.018 3.01 1.22-7.44 
Abbreviations: A = adenine; C =cytosine; G = guanine; T =thymine 
 
 
Table 6. Frequency of minor allele, and Odds Ratio (OR) with 95% CI, in stroke 
patients with PFO compared to healthy controls. 
 
Gene Polymorphism Minor Frequency Frequency P   OR 95 % CI 
   allell (PFO+) (Controls)     
Selektin E leu554phe(C/T) T 0.125 0.028 0.034   4.89 1.38-17.35 
Paraoxonase1 gln192arg(A/G) G 0.455 0.259 0.049   2.39 1.02-5.60 
Protrombin 20210 G/A A 0.125 0.007 0.001   19.29 4.78-77.88 
ApolipoprotCIII -641C/A A 0.591 0.366 0.043   2.51 1.06-5.93 
ApolipoprotCIII -455T/C C 0.591 0.371 0.044   2.45 1.07-5.80 
Abbreviations: A =adenine; C= cytosine; G= guanine; T= thymine 
 
 
4.2.3 Stroke characteristics 
In the clinical studies, patient populations differed regarding type of stroke. Study I 
consisted of patients with TIA or ischemic stroke, Study II included both TIA, ischemic 
and hemorrhagic stroke, while Study III only included patients with ischemic stroke. 
The proportion of different stroke subtypes in Study I and II are seen in Table 7. 
 
Table 7. Proportion of stroke subtype in Study I and Study II. 
 
 Study I (N=117) 
% (N) 
Study II (N=175) 
% (N) 
TIA 24.8 % (29) 25.1 % (44) 
Ischemic stroke 75.2 % (88) 68.6 % (120) 
Hemorrhagic stroke - 6.3 % (11) 
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In Study I, patients were classified according to TOAST (Figure 6); PFO patients were 
either assessed as cardioembolic or as unknown due to multiple mechanisms. Non-PFO 
patients were heterogenous regarding etiology, although cardioembolic stroke and 
unknown was more common. We did not have data on stroke severity from Study I.  
 
Figure 6. Stroke etiology according to TOAST in Study I (N=117). 
 
 
 
 
In Study II, both TIA, ischemic and hemorrhagic strokes were included. There were no 
significant difference regarding type of cerebrovascular event between stroke patients 
with or without migraine. The majority of the lesions were in the anterior circulation 
(70.8 %). The stroke population in Study II were assessed regarding stroke severity at 
onset. Most stroke events were TIA or minor strokes and the majority of patients were 
independent on follow-up. There were no significant differences in relation to migraine 
status. 
 
The patients in Study III were all regarded as cryptogenic. Similar to Study II, the 
majority of the lesions were located in the anterior circulation (76.9 %). Stroke severity 
with mRS <4 was a pre-requisite for screening for REDUCE, and all included patients 
had minor sequele with NIHSS 0-1 and mRS 0-2.  
 
 
4.3 ENDOTHELIAL FUNCTION IN CRYPTOGENIC STROKE 
Evaluation of endothelial function was assessed in Study III; using Endo-PAT 2000® to 
evaluate vascular reactivity, as well as selected biomarkers of ED; ET-1, hs-CRP, vWf 
and Hcy.  
 
 
4.3.1 Vascular reactivity before and after PFO closure 
In total 26 individual patients were assessed at baseline and followed according to 
protocol. One patient started as a control but later had his PFO closed due to a recurrent 
ischemic event. In the figure below, his baseline RHI as a control patient is presented. 
The baseline data of RHI-score were not normally distributed, as seen in the scatterplot 
of baseline data (Figure 7). Median baseline RHI was 1.60 (IQR 1.41-2.00). 
LAA
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Figure 7. Baseline RHI of patients in Study III (N=26). 
 
 
 
There was no significant change in RHI after closure of PFO, either from baseline to 
one day post closure (p = 0.46), or from baseline and over the first six month after 
closure (p=0.66) (Figure 8). Neither controls had a significant change from baseline to 
day 1 (p=0.23), or over the evaluated six-month period (p=0.32). Also, when looking at 
migraine patients having their PFO closed separately (n=13), there was no change over 
time (p= 0.87).   
 
Figure 8. RHI at baseline and after closure of PFO. 
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4.3.2 Biomarkers of endothelial activation 
Median plasma level of ET-1 at baseline (n=26) was 2.42 pg/mL (IQR 2.26-2.55). 
There was no difference between closure patients and controls. Baseline data for 
hsCRP (n=26) was median 0.54mg/L (IQR 0.2-1.1), for Hcy (n=26) mean 11.07 (SD 
+/- 3.4) and for vWF (n=25) mean 0.96 (SD +/- 0.3). Closure of PFO did not result in 
any significant change in plasma levels of either ET-1 (p=0.17), hsCRP (p=0.57), vWF 
(p=0.15) or Hcy (p=0.83). 
 
 
4.3.3 Migraine frequency after PFO closure 
Baseline migraine was heterogenous, ranging from several times per week to 2-3 times 
per year. Seven patients (53.8 %) had less than 1 migraine attack per month. After 
closure of PFO, three patients reported a substantial increase of migraine attacks, with 
aura daily or several days per week, the worst period being the first month after closure. 
In one case, migraine transformed from migraine without aura to migraine with aura.   
 
After the six-month period three patients had less migraine attacks than before, three 
patients had more, and seven patients had no change in migraine frequency. At a 
second follow-up (mean 43.4 month; SD +/- 13.6); 69 % (n=9) of the patients with 
migraine reported of less frequent migraine attacks. Six patients experienced complete 
cessation of migraine, or less than one migraine attack per year (Figure 9). In the case 
with transformed migraine, migraine with aura persisted also at long time follow-up.   
 
 
 
Figure 9. Migraine frequency at baseline and at long-time follow-up. 
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4.4 MIGRAINE AS A RISK FACTOR FOR STROKE 
The population based cohort consisted of 53 404 twins, consisting of both mono- and 
dizygotic twins. The mean follow-up time was 11.9 years and the total time of 
observation was 634 468.4 person-years. Mean age at the end of follow-up was 57.2 
years (SD 13.9, range 27.3-80.0). The table below show baseline characteristics of the 
cohort depending on migraine status (Table 8).  
 
 
Table 8. Baseline characteristics of cohort depending on migraine status (N=53404), 
given as mean (SD) or n (%). 
   
  
Migraine with 
aura 
Non- aura 
migraineous 
headache No migraine 
    (n=3 553) (n=5 082) (n=44 769) 
Mean age (SD): 42.5 (11.6) 44.9 (11.6) 45.6 (11.9) 
Female sex: 2 811 (79.1) 3 689 (72.6) 22 484 (50.2) 
    
Obese (BMI>30) *2  299 (8.4) 428 (8.4) 3 030 (6.8) 
Smoking*2 Current:  670 (18.9) 890 (17.5) 7955 (17.8) 
 Ever: 1 060 (29.8) 1 620 (17.5) 14 025 (31.3) 
Hypertension*2 687 (19.3) 955 (18.8) 6 399 (14.3) 
Hyperlipidemia*2 277 (7.8) 408 (5.0) 3 461 (7.7) 
Diabetes*2 
(type 1 or 2)  80 (2.3) 97 (1.9) 1 120 (2.5) 
Angina*2  105 (3.0) 117 (2.3) 1042 (2.3) 
Myocardial infarction*2 38 (1.1) 44 (0.9) 540 (1.2) 
Atrial fibrillation*3 107 (3.0) 158 (3.1) 1927 (4.3) 
Peripheral artery disease*2 44 (1.2) 59 (1.2) 330 (0.7) 
*1: Fulfill criteria for migraine with aura, migraine without aura or probable migraine. 
*2: Self-reported data 
*3: Data from National Patient Register 
 
 
Both twins with migraine with aura and non-aura migraine headache were of female 
dominance, but there were no difference regarding in cardiovascular risk factors 
depending on aura status. However, several co-morbid conditions differed between 
migraineurs and non-migraineurs. Hypertension, obesity and peripheral artery disease 
were more common, while atrial fibrillation, myocardial infarction and diabetes was 
less common in migraineurs compared to non-migraineurs (Table 9).  
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Figure 9. Risk factors in twins with any migraine compared to non-migraineurs. 
 
  
Any migraine 
(N= 8635) 
No migraine 
(N=44 769) 
 
OR (95 % CI) 
 
P 
Obesitas 727 (8.4) 3030 (6.8) 1.27 (1.16-1.38) < 0.0001 
Current smoking 1560 (18.1) 7955 (17.8) 1.02 (0.96-1.35) Ns 
Hypertension 1643 (19.0) 6399 (14.3) 1.41 (0.66-1.50) < 0.0001 
Hyperlipidemia 685 (7.9) 3461 (7.7) 1.03(0.94-1.12) Ns 
Diabetes 177 (2.1) 1120 (2.5) 0.82 (0.70-0.96) 0.012 
Angina 222 (2.6) 1042 (2.3) 1.1(0.96-1.28) Ns 
AMI*1 82 (1.0) 540 (1.2) 0.79 (0.62-0.99) 0.043 
AF*2 265 (3.1) 1927 (4.3) 0.70 (0.62-0.80) < 0.0001 
PAD*3 103 (1.2) 330 (0.7) 1.63(1.30-2.02) < 0.0001 
*1 AMI Acute Myocardial Infarction                                                                           
*2AF Atrial Fibrillation                                                                                                          
*3 PAD Peripheral Artery Disease  
 
 
During follow-up 1 297 first strokes were detected, of these 1 041 were ischemic 
strokes and 242 were hemorrhagic subtype. Another fourteen cases were double-
diagnosed both as an ischemic and a hemorrhagic event at the same date. In all, 1 073 
ischemic- and 276 hemorrhagic strokes were recorded in the material, and 38 twins had 
a record of both an ischemic stroke and a subsequent hemorrhagic stroke, or vice versa. 
Mean age for stroke diagnosis was 64.1 years (SD 8.4; range 27.3-79.4), and there was 
a male dominance among stroke patients (61.5 %).  
 
There was no increased risk for stroke in twins with any migraine headache (HR 1.07, 
95 % CI 0.91-1.26), or non-aura migraine headache (HR 0.97, 95 % CI 0.79-1.19). 
Twins with migraine with aura had a 27 % increased risk when adjusted for age and 
gender, however non-significant in multi-variable adjusted analyses. Estimated HR 
with 95 % confidence intervals for total stroke, as well as ischemic and hemorrhagic 
stroke are shown in Table 10.  
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Table 10. Estimated Hazard Ratios with 95 % CIs for total stroke, ischemic stroke and 
hemorrhagic stroke, whole cohort (n=53 404). 
 
    
Events 
(n) 
Gender adjusted  
HR (95 % CI) P 
Multivariable 
adjusted1 
HR (95 % CI) P  
No migraine headache 1126 1.00 (ref)  1.00 (ref)   
Migraine with aura       
Total stroke  70 1.27 (1.00-1.62) 0.05 1.20 (0.93-1.53) 0.15  
    Ischemic stroke2 58     1.28 (0.98-1.67) 0.08     1.19 (0.91-1.56) 0.20  
    Hemorrhagic stroke2 14     1.18 (0.69-2.04) 0.54     1.16 (0.67-2.00) 0.59  
Non-aura migraineous 
headache       
Total stroke  101 0.97 (0.79-1.19) 0.78 0.96 (0.78-1.19) 0.72  
    Ischemic stroke2  77     0.89 (0.70-1.12) 0.33     0.88 (0.69-1.12) 0.29  
    Hemorrhagic stroke2 27     1.23 (0.82-1.86) 0.32     1.24 (0.82-1.87) 0.31  
       
Any migraineous 
headache       
Total stroke  171 1.07 (0.91-1.26) 0.39 1.04 (0.89-1.23) 0.59  
    Ischemic stroke2 135     1.02 (0.85-1.23) 0.82     0.99 (0.82-1.19) 0.93  
    Hemorrhagic stroke2 41     1.22 (0.87-1.71) 0.26     1.22 (0.86-1.71) 0.26  
All models have attained age as underlying time scale.  
1Adjusted for gender, current smoking, obesity, hypertension, hyperlipidemia, diabetes, previous 
myocardial infarction, previous angina, atrial fibrillation and peripheral artery disease.                                                             
2 14 cases were diagnosed as both ischemic and hemorrhagic at the same date without knowledge of the 
primary event. These are accounted for in both the ischemic and hemorrhagic group. 
 
 
 
For migraine with aura, within-pair analysis was performed to assess whether the 
association to stroke was confounded by familial factors. The analysis was based on the 
2 142 twin pairs discordant for migraine with aura. The HR was attenuated in the 
within pair analysis (1.09, 95 % CI 0.81-1.46) (Table 11). 
 
 
Table 11. Hazard Ratio with 95 % CI for stroke in within-pair analysis. 
 
Stroke (1 297) HR (95 % CI) P   
Migraine w. aura Co-twin control    
Gender adjusted 1.09 (0.81-1.46) 0.588   
Multi-variable adjusted* 1.11 (0.82-1.51) 0.497   
 
 
 
 
   35 
4.4.1.1 Stratified analyses by gender and attained age. 
Risk estimates for stroke related to migraine with aura were higher in women than in 
men, although the interaction term between gender and migraine was non-significant. 
For non-aura or any migraineous headache there were no differences between men and 
women with regard to stroke risk (Table 11).  
 
Table 11. Estimated Hazard Ratios with 95 % CI for stroke, stratified by gender 
 
 
  
Events 
(n) 
Women 
HR (95 % CI) P 
Events 
(n) 
Men 
HR (95% CI) P 
No migraine headache 393 1.00 (ref)  733 1.00 (ref)  
       
Migraine with aura1 50 1.33 (0.99-1.78) 0.06 20 1.16 (0.74-1.80) 0.52 
Non-aura migraineous 
headache2 57 0.94 (0.71-1.25) 0.66 44 1.02 (0.75-1.38) 0.92 
Any migraineous 
headache3 107 1.09 (0.88-1.35) 0.45 64 1.06 (0.82-1.36) 0.67 
All models have attained age as underlying timescale.                                                                                      
1 Interaction term migraine with aura - gender, p= 0.60                              
2 Interaction term non-aura migraineous headache - gender, p=0.63                                                                  
3 Interaction term any migraineous headache - gender, p= 0.87 
 
 
The majority of stroke events occurred in twins older than 50 years of age; 1 227 cases 
compared to 70 cases in those under 50 years of age. The risk estimates for stroke in 
twins with migraine with aura, were higher in twins ≤ 50 years, but again the 
interaction term was non-significant. The estimated HR for stroke by attained age, 
depending on migraine status are shown in Table 12.  
 
Table 12. Estimated Hazard Ratios with 95 % CI for stroke, by attained age ≤ and > 50 
years of age. 
 
  
Events 
(n) 
Attained age ≤50, 
Gender adjusted 
HR (95 % CI) P 
Events 
(n) 
Attained age >50, 
Gender adjusted 
HR (95 % CI) P 
No migraine headache 58 1.00 (ref)  1068 1.00 (ref)  
       
Migraine with aura1 9 1.85 (0.92-3.73) 0.09 61 1.22 (0.94-1.59) 0.13 
Non-aura migraineous 
headache2 3 0.46 (0.14-1.45) 0.18 98 0.99 (0.80-1.22) 0.91 
Any migraineous 
headache3 12 1.06 (0.57-1.98) 0.45 159 1.07 (0.91-1.27) 0.40 
All models have attained age as underlying time-scale.                                                                             
1 Interaction term migraine with aura-attained age, p= 0.26                                                                               
2 Interaction term non-aura migraineous headache -attained age, p= 0.20                                                              
3 Interaction term any migraineous headache -attained age, p= 0.98 
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5 DISCUSSION 
The work on this thesis have evolved over the past eight years, alongside the clinical 
work, taking care of stroke patients, with and without co-existing migraine and/or PFO. 
During this time the scientific knowledge in the field have expanded greatly. Large 
prospective studies and meta-analyses regarding the risk for stroke and cardiovascular 
disease in migraineurs have been published, still the question of why there is an 
increased risk is unknown. For the association between stroke and PFO, three RCTs 
have been published, as well as analyses of pooled data. In conclusion, the risk for 
recurrent stroke related to PFO, was lower than expected, making the individual studies 
underpowered. However, pooled data and longtime follow-up, give some support in 
favor of closing PFO, in selected patients with cryptogenic stroke. As for PFO and 
migraine, additional studies have failed to show benefit of PFO closure in migraine, 
and there is today no place for closure on this indication.  
 
In the following sections, I will discuss the results presented in this thesis in a broader 
context, and in relation to other published studies. 
 
 
5.1 PREVALENCE OF MIGRAINE AND PFO 
5.1.1.1 Migraine prevalence 
The prevalence of migraine was investigated both in a population based study and in 
selected stroke populations. In Study IV, the overall prevalence of migraineous 
headache (16.2 %) was in line with previous population based studies, reporting 
prevalence estimates of migraine in the general population, ranging between 10-16 % 
(56, 200-202). About 40 % of the patients had migraine with aura. The population in 
STAGE had a higher prevalence of migraine compared to SALT (19.5 % vs 13.8 %), 
which probably reflects the different age spectrum of the cohorts. As discussed 
previously, migraine prevalence follow a U-shaped curve, with higher estimates in 
early adulthood and midlife (54).  
 
In the stroke populations of Study II, life-time prevalence of migraine was 20.1%, 
while 9 % had active migraine, compared to 50 % in Study III. However, these two 
populations differ in age distribution and co-morbid conditions, since age < 60 years 
and co-existing PFO was a pre-requisite for initial screening to Study III. This probably 
explain the difference; the aspect of age has been addressed previously, as well as the 
known association between migraine and PFO.  
 
Migraine prevalence in stroke populations have been investigated in several case-
control studies. The prevalence of migraine there ranged between 8-30 % depending on 
the age and gender distribution of the cohorts, while the selected control populations 
had a prevalence of migraine between 4-16 % (101, 103, 203-207). The higher 
prevalence was seen in younger populations (204, 206). Our results in Study II, are thus 
in-line with data from previous stroke-populations, but also comparable to the 
estimated prevalence found in large population based studies on the general population.  
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In our material, migraine was more common in younger patients; 42.9 % in those ≤ 50 
compared to 18.6 % in those over 50 years of age. Though, only 14 patients were under 
50 years of age at stroke onset, and the material is too small to draw any conclusions.  
 
In both of our stroke populations, the majority of the migraine patients had migraine 
with aura; 61.1 % and 84.6 % respectively. In the general population, the presentation 
of migraine aura increases with age, which may explain our results (54). However, in 
Study II, migraine with aura was the most common subtype in all patients regardless of 
age. Previous studies in younger stroke populations have also found similar proportions 
of migraine with aura among migraineurs; both in the work by Chang et al and Abanoz 
et al; 68.9 and 60.6 % of migraineurs in the stroke population reported migraine with 
aura, which was suggested to be associated with an increased risk for stroke in this 
group (204, 206). The high proportion of migraine with aura in Study III, is in line with 
previous studies of individuals with PFO and migraine with aura. 
 
5.1.1.2 Prevalence of PFO  
The prevalence of PFO was low, both in Study I and Study II. In Study I, only a 
selective sample of the patients were examined with TEE, and we have no knowledge 
of the frequency of PFO in the remaining cohort, nor in controls. In Study II, the 
majority of the patients were examined with TTE, which is less sensitive in finding a 
PFO compared to TEE, and this might explain the low prevalence of 11.2 %. Also, the 
populations in Study I and II consisted of mixed stroke populations, and not 
cryptogenic strokes only. Previously, the prevalence of PFO in mixed stroke 
populations has varied substantially, with estimates ranging between 6-30 % (208), and 
are thus in line with the prevalence in our studies.   
 
 
5.2 STROKE CHARACTERISTICS  
5.2.1.1 Patients with stroke and co-existing PFO 
In Study I, the criteria for inclusion in the post-hoc analysis, was that TEE was 
performed in the diagnostic work-up. In routine clinical praxis, TEE is mainly 
performed in younger patients, looking for minor sources of cardioembolism, or it is 
performed in the acute setting, but then mainly if there is a high suspicion of a 
cardioembolic source, such as a thrombus or endocarditis. This is probably reflected in 
the young median age of 59 years, where 74.3 % of the patients in Study I were < 65 
years of age. This also reflects the relatively small proportion of LAA and SAO as 
etiology of stroke, while cryptogenic stroke (unknown, complete work-up) and 
cardioembolic stroke (including patients with PFO as a potential source of 
cardioembolism) stood for almost 60 % of the stroke cases.  
 
The patients of Study III, were all considered as CS with co-existing PFO. Mean RoPE-
score was 7.5, making it reasonable to assess the PFO to be stroke related. RoPE score 
above 7 have previously been suggested as a cut-off to distinguish a PFO as related to 
the stroke instead of incidental (209). All patients had stroke with a good functional 
outcome, which most likely was biased by the screening criteria for the reduce trial 
(mRS<4).    
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5.2.1.2 Patients with stroke and co-existing migraine 
In Study II, stroke severity at baseline was assessed using NIHSS, and level of 
independence at home after discharge was assessed from medical records. Most 
patients, regardless of migraine status, had TIA or minor strokes, and a good functional 
outcome after stroke. This may be caused by selection bias, where patients with major 
strokes were less likely to participate in the study. Migraine has though been associated 
with TIA and minor strokes, as well as strokes of good functional outcome (129, 210). 
      
 
5.3 ARE CARDIOVASCULAR RISK FACTORS MORE COMMON IN 
MIGRAINE? 
Previous studies have shown that migraineurs have more cardiovascular risk factors, 
like smoking and hypertension, compared to non-migraineurs. However, data are 
inconsistent. In Study IV, migraineurs were more prone to be obese and to have 
hypertension or peripheral artery disease, while both previous myocardial infarction, 
presence of atrial fibrillation and diabetes mellitus was less common in those with 
migraine. Hypertension is one of the most important risk factors for stroke, and it has 
been associated with migraine in several population based studies (133-135). However, 
other studies have shown the opposite association (211-213). Hypertension has also 
been associated with other primary headaches (214, 215), and the association might 
thus not be specific to migraine.  
 
Both peripheral artery disease and obesitas have also previously been associated with 
migraine, but for obesitas results have been inconsistent (134, 139). In our study, 
diabetes mellitus was less common in migraineurs, which is in line with previous 
studies showing an inverse relationship between the two conditions. The inverse 
relationship has been shown both for type 1 and type 2 diabetes mellitus, but the reason 
for this is unknown (216, 217). Atrial fibrillation was also less common in Study IV, as 
well as among stroke patients with co-existing migraine in Study II. There are no 
previous reports regarding this, unless in the setting of induction of a migraine attack 
after ablation treatment of atrial fibrillation (218). The prevalence of atrial fibrillation 
increases with age, and this might explain the differences between migraineurs and 
non-migraineurs in our studies (219). Apart from atrial fibrillation, PFO was also 
associated with migraine in Study II. Otherwise, there were no other differences in risk 
factors depending on migraine status.  
 
In conclusion, previous studies are not consistent regarding the association between 
migraine and different cardiovascular risk factors, and whether this could be associated 
to a development of atherosclerosis and subsequent risk for cardiovascular disease in 
migraneurs, is still unclear. Migraine has also repeatedly been shown to be an 
independent risk factor for stroke, and on the contrary the risk has been highest in those 
with a low risk factor profile for cardiovascular disease (124). Also, in our longitudinal 
follow-up, controlling for cardiovascular risk factors did not change the risk estimates 
for stroke. This is in line with the hypothesis that non-atherosclerotic mechanisms may 
be more important in the association between migraine and stroke (129, 210). 
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Regardless, in migraineurs, cardiovascular risk factors should be screened for and 
treated appropriately.  
 
 
5.4 CAN OTHER FACTORS EXPLAIN THE RISK FOR STROKE IN 
RELATION TO PFO? 
A large minority of the general population have a PFO and a stroke may have 
devastating effects on the individual’s quality of life. It’s therefore of interest to identify 
the patients with the highest risk for stroke, related to PFO.    
 
5.4.1.1 Genetic risk markers associated with PFO 
The most probable mechanism associating PFO with stroke is paradoxial embolism. 
This implies formation of embolus on the venous side, but a deep venous thrombosis is 
only found in a small set of patients with stroke and PFO (161). However, with this 
rationale; pro-thrombotic mutations affecting the risk for venous embolism, could 
impact the risk for stroke with co-existing PFO. In Study II, we investigated 100 
different SNPs, previously associated with ischemic stroke, including the most 
common pro-thrombotic mutations for venous thromboembolism; Factor V Leyden and 
pro-thrombin (20210 G/A). Indeed, we found that the common pro-thrombin mutation, 
was associated with PFO and stroke. This mutation, has previously been associated 
with PFO and CS (160, 220-222), but it has also been associated with cryptogenic 
stroke in general, regardless of co-existence of PFO (223). Factor V Leyden has also 
previously been associated with CS and PFO (220, 221), though not in our material.  
 
We also tested for other SNPs, associated with stroke through different mechanisms; 
homocysteine metabolism, inflammation, lipid metabolism and hypertension and 
vasodilation. We found two SNPs in the Apolipoprotein CIII associated with PFO, and 
one border-significant SNP located in Selectin E. Apolipoprotein CIII regulates 
lipoprotein metabolism and is associated with hypertriglyceridemia, but it may also 
activate a pro-inflammatory response in endothelial cells, leading to ED and 
atherosclerosis. (224, 225). Selectin E is an adhesion molecule, facilitating interactions 
between leukocytes and endothelial cells. Elevated levels are associated with ED and 
the selected SNP have previously been associated with atherosclerosis (226, 227). 
Neither Apolipoprotein CIII or Selectin E have previously been associated with CS or 
PFO. All four SNPs, as well as one SNP in the Paraoxonase gene, were associated with 
PFO compared to controls. However, we don’t have any data on the prevalence of PFO 
in the control population and these may therefor mainly be assessed as a risk marker for 
an increased susceptibility to ischemic stroke in general.           
 
 
5.4.1.2 Endothelial function in cryptogenic stroke and PFO 
In study III, the main objective was to investigate endothelial function in CS and PFO, 
and to evaluate whether it was affected by closure. The method for evaluation was 
Endo-PAT 2000® which had been set up and used at the Department of Cardiology. 
Endo-PAT 2000® has previously been shown to identify patients with cardiovascular 
disease and to predict future cardiovascular events (228, 229). The majority of patients 
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were non-smokers and lacked cardiovascular risk factors, and in case of any 
hypertension this was well controlled with medication. All patients were also on anti-
thrombotic- and statin treatment as routine secondary stroke prophylaxis, which both 
have been shown to improve endothelial function (230, 231). Despite of this, median 
RHI indicated impaired endothelial function in the majority of patients. This could be 
related to the recent stroke. Previous work by Sherbakov et al., showed that endothelial 
function, assessed by Endo-PAT 2000, was impaired in the acute setting regardless of 
stroke subtype (232). Our patients though, were assessed in the convalescent phase 
after the stroke. Compared to historic controls of healthy individuals, the results in our 
patients indicate impaired endothelial function (232, 233). In a comparative study, 
Sunbul et al, investigated endothelial function in patients with cryptogenic stroke, with 
or without co-existing PFO and in healthy controls. They found an association with ED 
and CS, regardless of co-existing PFO. However, cardiovascular risk factors, known to 
impair endothelial function, were more prevalent in their patients compared to our 
cohort (15, 234). They used FMD to assess endothelial function which makes 
comparisons difficult.  
 
A major disadvantage in interpreting the results, is that we did not have stroke-free 
controls, with or without PFO for comparison. Nevertheless, the results may be seen as 
hypothesis generating, and warrants for further investigation. Regarding the 
investigated biomarkers of ED, we did not find an increased level of these at baseline. 
However, also here we did not have a control group to compare with. 
 
5.4.1.3  
The initial idea of investigating endothelial function over time after PFO closure, came 
from the clinical observations of changed migraine frequency, or new onset of migraine 
headache, after PFO closure. This has mainly been observed during the first months 
after closure, and correlates in time with the reendothelialization of the device.  
 
Changes in serum concentrations of substances, no longer escaping degradation in the 
pulmonary system, would also likely be seen within the first months after closure. In 
our study, there was no significant change; neither in vascular reactivity or in selected 
biomarkers in the first six months after closure. Previously, work by Lopez et al. found 
a reduced proteomic expression of substances involved in inflammation and 
coagulation signaling at 3 months’ follow-up after PFO closure, and Deng et al, found 
reduced levels of Hcy after PFO closure (98).  
 
             
5.5 DOES PFO CLOSURE AFFECT MIGRAINE FREQUENCY? 
Considering the complex pathophysiology of migraine, where environmental factors 
together with genetic determinants combined, impact the migraine phenotype, it’s not 
likely that PFO closure would cure migraine, and there is no support for that theory 
today. There is however animal data, supporting the idea that micro-embolisms through 
a PFO could induce migraine attacks, and thus explain a part of migraine attacks in 
individual patients. From Study III, we provide observational data of migraine 
frequency after closure. In our study, almost 70 % of the migraine patients (n=9) 
reported improved-, or cessation of migraine, at a second long-time follow-up. This is 
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consistent with a former study by Takaya et al, where 63 % stopped having migraine 
attacks at a follow-up three years after closure (235). Improvement of migraine may 
have several explanations besides closure of PFO; medications used for secondary 
prevention (i.e. statins and anti-thrombotic treatment) may have a beneficial effect with 
reduction of migraine days. Likewise, life changes with avoidance of stress after stroke, 
can improve migraine frequency, and it can also be the natural course of migraine in the 
individual patient. 
 
 
5.6 DOES MIGRAINE INCREASE THE RISK OF STROKE? 
In Study IV, the risk for stroke in migraineurs was investigated in a Swedish 
population-based twin cohort. As discussed before, there are a multitude of studies that 
have investigated this before, and at least migraine with aura is regarded as an 
independent risk factor for stroke. To our knowledge, our study is the first using a 
symptom based approach in identifying migraineurs, in a population based cohort with 
a prospective twin design, which also allows controlling for familial factors.    
 
The incidence rate of first-stroke in the whole cohort was 204 cases/100 000 person- 
years, which is in line with incidence rates reported for high-income countries in 
epidemiological research (236). In comparison with previous studies, our results show a 
much weaker association for stroke in relation to migraine. We only found an increased 
risk for those with migraine with aura, while for any migraine there was no increased 
risk at all. In the multivariable model, all analyses were non-significant. 
 
The association between migraine and stroke has previously foremost been associated 
with female gender and younger age, and many studies have also been restricted to 
these groups (100, 104-106, 109, 138, 206). Five prospective studies have like us, 
investigated the risk for stroke in a population of both genders, with varying results. 
Three studies (Merikangas et al. (108), Velentgas et al. (107) and Hall et al. (153)) 
showed an increased risk, while Stang et al. (237) only found an increased risk in those 
with migraine with aura, and Monteith et al. (126) did not find any increased risk for 
stroke, unless in the combination of migraine and current smoking.  
 
In our study, migraine was identified by symptom based questions, the first being if 
they have/had had recurrent headaches. This approach may detect migraineurs 
regardless of the severity, or frequency of headache attacks. In comparison with the 
studies showing an increased risk for stroke related to any migraine; both Hall et al. and 
Velentgas et al. used patient records and/or prescription of triptans to identify 
migraineurs, and Merikangas et al. used self-reported physician diagnosis of migraine. 
However, many patients with migraine never seeks medical attention for their 
headaches (238), and migraineurs in these studies might thus be experiencing more 
frequent, or severe migraine attacks, factors that have been associated with an increased 
risk for stroke (105, 127). This difference might explain the weaker association in our 
study, unfortunately in our study, we did not have information regarding migraine 
frequency or whether migraine was active or not.  
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In the analyses of migraine and the risk of ischemic and hemorrhagic stroke 
respectively, all results were non-significant. Although, compared to hemorrhagic 
stroke, risk estimates were slightly higher for ischemic stroke related to migraine with 
aura. This is in line with previous studies, where the highest risk has been seen for 
migraine with aura and ischemic stroke. Likewise, in stratified analysis by gender and 
attained age of 50 years, there were higher risk estimates among females and those 
under 50 years of age, which also are in line with the conclusions of the meta-analysis 
by Schurks et al (113). There were though few endpoints in twins with attained age 
younger than 50 years, and we can therefore not draw any firm conclusions from these 
data.  
 
In conclusion, in the scientific literature migraine and especially migraine with aura, 
have previously been recognized as an independent risk factor for stroke with an 
approximately doubled associated risk to ischemic stroke, and a less clear association to 
hemorrhagic stroke. In contrast, we only found a modest increased risk associated with 
migraine with aura, and for the large body of migraineurs without aura, we did not find 
any increased risk for stroke.    
 
 
5.6.1 May an increased risk depend on familial factors? 
The twin design of Study IV allows controlling for familial factors, by using within pair 
analysis. The analysis relies on complete twin pairs, discordant for the exposure, and 
thus allows controlling for factors that are constant within twin pairs, e.g. early 
childhood environment and genetic factors. In the analysis of migraine with aura in 
relation to stroke, the risk estimate attenuated in the within pair analyses (HR 1.27 to 
HR 1.09).  This suggests that familial factors can attribute to the increased risk, but 
there was a large drop in sample size and we cannot draw any firm conclusions from 
these data.  
 
The results are interesting in respect of more recent evidence from animal studies 
linking migraine with a phenotype being more susceptible to trigger CSD and also 
more vulnerable to ischemic injury. In a small retrospective case-control study, patients 
with migraine were also more likely to have a perfusion-diffusion mismatch on MRI, 
performed within 72 hours after admission (239).  
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5.7 LIMITATIONS  
There are methodological aspects and limitations of each of the included studies, which 
have to be considered when interpreting the results. The methodological aspects have in 
part been covered in the previous discussion, in relation to each study. However, below 
follows some additional viewpoints regarding the limitations of the studies.  
 
In Study I and II, the major limitations are the retrospective design and the small 
population sample, which makes it difficult to draw any firm conclusions. The 
evaluation of migraine, might be influenced by recall bias due to the retrospective 
design. The studies were also too small to be able to stratify analyses according to 
migraine and/or stroke subtype. In Study I, another major limitation is the fact that it is 
a mixed stroke population, and the PFO may be incidental rather than related to the 
stroke. We also lack data on prevalence of PFO in the control group, which make the 
comparison of genetic markers in patients versus controls irrelevant in regards of co-
existing PFO. In Study II, the results regarding stroke characteristics may be an effect 
of selection bias, since patients with the most severe sequele after stroke were excluded 
from the questionnaire, and even those with moderate sequele might be less inclined to 
participate in the study.      
 
Study III, was an experimental study in order to explore differences over time after 
closure. It was not designed to evaluate endothelial function at baseline, and a major 
limitation is the lack of a control group. The results might instead be seen as hypothesis 
generating. The evaluation of endothelial function is also difficult to compare with 
previous studies, due to the wide variety of methods used in other studies, both for 
evaluating vascular reactivity, as well as biomarkers of endothelial activation. This is a 
general consideration regarding previous studies evaluating endothelial function, both 
in migraine and stroke. 
 
In Study IV, we have a large population based cohort, but a limitation of the study is 
the fairly short follow-up time. Mean age at the end of study was low (57 years), and 
far younger than the mean age for stroke in the general population. On the other hand, it 
is in younger and middle-aged individuals that migraine probably contributes the most 
to the stroke risk. Other limitations are that we were unable to verify the stroke events 
by medical records, and in a few cases, twins were diagnosed both as an ischemic and a 
hemorrhagic stroke at the same date, making these accounted for in both groups in the 
sub-analyses. Also, younger twins in the material may have developed migraine during 
the follow-up, and any strokes in these twins might have attenuated the effects. We 
were also unable to identify twins with migraine auras without subsequent headaches. 
These are fairly rare cases, although they have the migraine subtype most associated 
with stroke, and misclassification of these twins, might also have attenuated the results.    
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6 CONCLUSION AND FUTURE PERSPECTIVES 
 
The project in this thesis have explored different aspects of migraine and PFO in 
relation to stroke, mainly ischemic stroke. In conclusion, we found that: 
 
 
- A common pro-thrombotic mutation, Prothrombin (20210 G/A), was associated 
with TIA/ischemic stroke and co-existing PFO. The mutation increases the risk 
of venous thromboembolism and may be related to the risk for stroke through 
paradoxial embolism.  
 
- Another two mutations in Apolipoprotein C III and one mutation in Selectine E, 
showed a weak association with ischemic stroke and PFO. The mutations have 
not previously been associated with stroke and PFO.  
 
- There was no increased migraine prevalence in our mixed stroke cohort, but the 
majority of the patients had migraine with aura. Cardiovascular risk factors 
were highly prevalent in stroke patients, regardless of migraine diagnosis. A 
diagnosis of PFO were more common in migraineurs, as expected from 
previous studies.   
 
- A majority of patients with cryptogenic stroke and co-existing PFO had 
impaired endothelial function, despite lack of cardiovascular risk factors and 
ongoing anti-thrombotic and statin treatment. There was no change over time 
after closure. 
 
- In a Swedish population based twin cohort, there was no association between 
any migraine and stroke, although a modest risk increase was seen for migraine 
with aura in gender- and age adjusted analyses.  
 
- The increased risk for stroke related to migraine with aura might be impacted 
by familial factors.  
 
 
 
6.1 FUTURE PERSPECTIVES 
6.1.1 Aspects of migraine in stroke 
Our results from Study IV, supports the idea that the increased risk for stroke in relation 
to migraine is mainly restricted to the subset of patients with migraine with aura, and 
also shows that familial factors might contribute to the risk. Given our results, the large 
body of migraineurs with migraine without aura, may not have an increased risk for 
stroke, and even in those with migraine with aura, the absolute risk for stroke is 
probably low. Future studies may attempt to further establish which migraineurs that 
are at an increased risk, and whether this relates to the frequency of migraine attacks. In 
Study IV, the questionnaire in STAGE but not in SALT, included questions regarding 
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more frequent headaches (at least monthly) as well as use of triptan treatment, and a 
second, longer follow-up in this population can be of interest.  
 
The mechanisms behind an increased risk for stroke are still unclear. If the aura itself 
leads to subsequent biological changes increasing the risk of stroke, the risk estimate 
could depend on the frequency of attacks with aura and not the total amount of 
migraine attacks. If instead an inborn effect increases the risk of ischemia, the attack 
frequency might not have an impact on the risk. Interestingly, in animal studies, several 
migraine prophylactic treatments have been shown to suppress the susceptibility to 
CSD, and also to improve stroke outcome (240, 241). If future studies can identify a 
subgroup of migraine patients with higher risk of stroke, this may guide future 
preventive treatments. As of now, there is now role for primary prevention with 
antithrombotic treatment or migraine prophylaxis, in regards of decreasing the risk for 
stroke only. The impact of cardiovascular risk factors on the risk for stroke in 
migraineurs is still uncertain. However, traditional cardiovascular risk factors should be 
investigated and treated accordingly to minimize the general risk for cardiovascular 
disease. 
 
This thesis has focused on the association between migraine and stroke, but apart from 
the risk for stroke, migraine is also associated with an increased risk of myocardial 
infarctions and angina. Some mechanisms, hypothesized to increase the risk of stroke, 
i.e. association to PFO and CAD, as well as subsequent effects of CSD, cannot explain 
the increased risk for ischemic heart disease. The findings of increased prevalence of 
cardiovascular risk factors and ED in migraineurs, might instead be of greater interest 
in this respect. Further studies regarding the role of endothelial function in migraine are 
warranted, preferably in larger populations. 
 
 
6.1.2 Aspects of PFO in stroke 
Since the work on this thesis started the long-term results of the RESPECT study have 
been published, adding data in support of closure of PFO after ischemic stroke in 
selected patients. The Amplatzer device has also been FDA-approved for secondary 
prophylaxis of ischemic stroke related to PFO. The annual risk for recurrent stroke is 
low, assessed to approximately 1% on medical treatment, but in a young patient the 
accumulated risk of recurrent stroke may still be substantial. PFO closure is considered 
a safe procedure, though rarely, the device may result in complications, also many 
years after implantation (242, 243). Whether assessment of endothelial function could 
add predictive value in identifying patients at a higher risk for stroke, and thus better 
select patients who benefits from PFO closure, warrants further investigations. We are 
now planning for a follow-up study, with assessment of endothelial function in patients 
with cryptogenic stroke and PFO, compared to healthy controls with and without PFO. 
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7 POPULÄRVETENSKALIG SAMMANFATTNING 
 
En stroke innebär att man får en propp eller en blödning i hjärnan eller ryggmärgen, 
vilket globalt drabbar över 10 miljoner människor varje år. Bara i Sverige får ca 25 000 
människor en stroke varje år. Stroke är en komplex sjukdom där arv och miljö 
samverkar till en ökad risk. De vanligaste orsakerna till stroke är följdeffekter av 
åldrande, såsom åderförkalkning i blodkärlen eller hjärtsjukdomar som t.ex. 
förmaksflimmer. Vanliga riskfaktorer för att drabbas av stroke är rökning, högt 
blodtryck och diabetes, men det finns många fler. Den här avhandlingen handlar om två 
mindre vanliga riskfaktorer för stroke - öppetstående foramen ovale (PFO) och migrän. 
 
PFO är en rest från fostertiden som finns hos ca 25 % av befolkningen. Det innebär att 
det finns en förbindelse mellan höger och vänster förmak, och därigenom kan proppar 
som bildas i det venösa systemet ta sig över till vänster förmak och orsaka en stroke, 
s.k. paradoxal embolisering. Studier har visat att PFO är mer vanligt förekommande 
hos patienter med stroke utan klar orsak, men det är också vanligare hos individer med 
migrän.  
 
Migrän är en primär huvudvärksform som förekommer hos ca 11–13 % av 
befolkningen, men det är betydligt vanligare hos kvinnor än hos män. Migrän debuterar 
ofta i tonåren eller tidig vuxenålder. Diagnosen ställs kliniskt utifrån symtomen vid 
huvudvärksattackerna. I ca 1/3-del av fallen har patienterna en inledande aura av 
neurologiska bortfall och man skiljer därför mellan migrän med aura och migrän utan 
aura. Genom åren har upprepade studier visat på en ökad risk för stroke hos patienter 
med migrän. Risken har framför allt visat sig föreligga hos de med migrän med aura, 
samt vara kopplat till kvinnligt kön och ålder <45 år.  
 
Det finns en rad olika hypoteser till varför migräniker har en ökad risk för stroke. Dels 
har studier visat att individer med migrän har fler riskfaktorer för stroke och 
hjärtkärlsjukdom vilket kan leda till utveckling av ateroskleros och ökad risk för stroke. 
Det kan också vara så att själva migränauran är kopplat till genetiska förändringar som 
medför att man har en ökad känslighet för syrebrist i hjärnan, eller att migränanfallet 
leder till biologiska förändringar som ger en ökad risk för stroke. Migrän är också 
kopplat till en ökad förekomst av PFO vilket i sin tur tros kunna orsaka stroke framför 
allt hos unga. Intressant nog, har man också sett att förekomsten och uttrycket av 
migränattacker kan förändras efter slutning av ett PFO, med en initial försämring av 
frekvensen hos en del, men på lång sikt en förbättring av migränfrekvensen.  
 
Den här avhandlingen bygger på fyra delstudier som belyser olika aspekter av PFO och 
migrän i anslutning till stroke. I Studie I, undersökte vi om olika genförändringar, som 
tidigare associerats med ökad risk för stroke, var mer vanligt förekommande hos 
strokepatienter med samtidig förekomst av PFO. Vi fann att en vanlig mutation som ger 
en ökad risk för venösa proppar var kopplat till stroke och PFO. Vi fann också att 2 
andra mutationer som påverkar fettmetabolism och inflammation var associerade med 
stroke och PFO. 
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I Studie II undersökte vi förekomsten av migrän i en blandad strokepopulation. Migrän 
identifierades utifrån en enkät med frågor avseende återkommande huvudvärksattacker 
och hur dessa brukar te sig. Vi fann att ca 20 % av populationen hade eller hade haft 
migrän. En större del än förväntat, 61 % av de med migrän, hade migrän med aura. 
Patienter med stroke och samtidig migrän hade en ökad förekomst av PFO jämfört de 
utan migrän, men för övrigt var det inga skillnader mellan strokepatienter med eller 
utan migrän. 
 
I Studie III undersökte vi endotelfunktionen, dvs funktionen hos det innersta cellagret i 
kroppens alla blodkärl, före och efter slutning av PFO hos patienter med kryptogen 
stroke, det vill säga stroke utan någon klar orsak. Nedsatt endotelfunktion är kopplat till 
utveckling av ateroskleros och ökad risk för stroke, men det har också kopplats till 
möjliga biologiska effekter av upprepade migränanfall. Patienterna var, frånsett sin 
stroke, tidigare friska och utan riskfaktorer för stroke. Hälften av patienterna hade 
migrän och av dessa hade nästan samtliga (84.6 %) migrän med aura. Majoriteten av 
patienterna hade en nedsatt endotelfunktion vid första mätningen, men slutning av PFO 
påverkade däremot inte endotelfunktionen. Det är oklart om detta kan ha ett 
prognostiskt värde för att utvärdera risken för en ny stroke relaterat till PFO.  
 
I sista studien, Studie IV, undersökte vi risken för stroke relaterat till migrän i en 
population från det svenska tvillingregistret. Över 53 000 individer inkluderades i 
studien och följdes under drygt 10 års tid. Förekomst av migrän identifierades från 
tidigare insamlade enkäter och strokefall identifierades via länkning till nationella 
patientregister. I vår studie såg vi ingen ökad risk för migrän överlag, däremot fanns det 
en något ökad risk hos tvillingar med migrän med aura. Vidare analyser pekar på att 
familjära faktorer kan bidra till den ökade risken. I jämförelse med tidigare studier var 
det dock en betydligt minskad risk för stroke hos individer med samtidig migrän.     
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8 APPENDIX 
 
8.1 NATIONAL INSTITUTE OF HEALTH STROKE SCALE (NIHSS) 
Instruction Scale definition 
1a.  Level of 
Consciousness (LOC): 
0 = Alert; keenly responsive.   
1 = Not alert; but arousable by minor stimulation to 
obey, answer, or respond.   
2 = Not alert; requires repeated stimulation to attend, or 
is obtunded and requires strong or painful stimulation 
to make movements (not stereotyped).   
3 = Responds only with reflex motor or autonomic 
effects or totally unresponsive, flaccid, and areflexic.  
1b. LOC, questions: 
- What month is it? 
- How old are you? 
0 = Answers both questions correctly.   
1 = Answers one question correctly.   
2 = Answers neither question correctly. 
1c. LOC, command: 
Close your eyes. 
Close and open your fist. 
0 = Performs both tasks correctly.  
1 = Performs one task correctly.  
2 = Performs neither task correctly. 
2. Best Gaze:  Only 
horizontal eye movements 
will be tested. Voluntary 
or reflexive eye 
movements will be scored. 
0 = Normal.  
1 = Partial gaze palsy; gaze is abnormal in one or both 
eyes, but forced deviation or total gaze paresis is not 
present.  
 2 = Forced deviation, or total gaze paresis not 
overcome by the oculocephalic maneuver.  
3.  Visual:  Visual fields 
(upper and lower 
quadrants) are tested by 
confrontation, using finger 
counting or visual threat, 
as appropriate. 
0 = No visual loss.  
1 = Partial hemianopia.  
2 = Complete hemianopia.  
3 = Bilateral hemianopia (blind including cortical 
blindness). 
4.  Facial Palsy: 0 = Normal symmetrical movements.   
1 = Minor paralysis (flattened nasolabial fold, 
asymmetry on smiling).   
2 = Partial paralysis (total or near-total paralysis of 
lower face).   
3 = Complete paralysis of one or both sides (absence of 
facial movement in the upper and lower face). 
5. Motor Arm:  The limb 
is placed in the 
appropriate position: 
extend the arms (palms 
down) 90 degrees (if 
sitting) or 45 degrees (if 
supine).  Tested in each 
arm separately. 
0 = No drift; limb holds 90 (or 45) degrees for full 10 
seconds.    
1 = Drifts down before full 10 seconds; does not hit 
bed or other support.    
2 = Some effort against gravity; limb cannot get to or 
maintain (if cued) 90 (or 45) degrees, drifts down to 
bed, but has some effort against gravity.    
3 = No effort against gravity; limb falls.    
4 = No movement.    
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6.  Motor Leg:  The limb 
is placed in the 
appropriate position:  hold 
the leg at 30 degrees 
(always tested supine). 
Tested in each leg 
separately. 
0 = No drift; leg holds 30-degree position for full 5 
seconds.    
1 = Drift; leg falls by the end of the 5-second period 
but does not hit bed.       
2 = Some effort against gravity; leg falls to bed by 5 
seconds, but has some effort against gravity.    
3 = No effort against gravity; leg falls to bed 
immediately.    
4 = No movement.    
7.  Limb Ataxia: Test with 
eyes open. The finger-
nose-finger and heel-shin 
tests are performed on 
both sides, and ataxia is 
scored only if present out 
of proportion to weakness. 
0 = Absent.  
1 = Present in one limb.  
2 = Present in two limbs. 
8.  Sensory:  Sensation or 
grimace to pinprick when 
tested, or withdrawal from 
noxious stimulus in the 
obtunded or aphasic 
patient. 
0 = Normal; no sensory loss.  
1 = Mild-to-moderate sensory loss; patient feels 
pinprick is less sharp or is dull on the affected side; or 
there is a loss of superficial pain with pinprick, but 
patient is aware of being touched.  
2 = Severe to total sensory loss; patient is not aware of 
being touched in the face, arm, and leg. 
9.  Best Language: 0 = No aphasia; normal.  
1 = Mild-to-moderate aphasia; some loss of fluency or 
facility of comprehension, without significant 
limitation on form of expression.  Reduction of speech 
and/or comprehension, however, makes conversation 
about provided materials difficult or impossible.   
2 = Severe aphasia; all communication is through 
fragmentary expression. 
3 = Mute, global aphasia; no usable speech or auditory 
comprehension.  
10.  Dysarthria: 0 = Normal.   
1 = Mild-to-moderate dysarthria; patient slurs at least 
some words and, but can be understood with some 
difficulty.   
2 = Severe dysarthria; patient's speech is so slurred as 
to be unintelligible in the absence of or out of 
proportion to any dysphasia, or is mute/anarthric. 
11. Extinction and 
Inattention (neglect): 
0 = No abnormality.  
1 = Visual, tactile, auditory, spatial, or personal 
inattention to bilateral simultaneous stimulation in one 
of the sensory modalities.  
 2 = Profound hemi-inattention or extinction to more 
than one modality. 
Adopted from National Institute of Health 
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8.2 HEADACHE QUESTIONNAIRE USED IN STUDY II AND III 
Q 1.   Have you any kind of recurrent headache episodes, not associated to 
infection and/or fever? (Yes/No) 
Q 2. At what age did these headaches start?  
Q 3. How long is the duration of headache episodes? (< 3 hours, 3-6 hours, 6-
12 hours, 12-24 hours, 24-36 hours, 36-48 hours, varying) 
Q 4. What is the primary location of the headache? (Orbital, in the forehead, 
temporal, occipital, face/jaw, varying) 
Q 5. On what side is the pain located? (right-side, left-side, side-changing, 
bilateral, varying) 
Q 6. What character does the pain have? (explosive, incisive, pounding, dull) 
Q 7. What intensity does the headache have when as worst? (Scale of 1-10) 
Q 8. Is the headache accompanied by any of the following? (nausea, vomiting, 
light-, sound-sensitive) 
Q9. Is the headache accompanied by any of the following? (conjunctive 
injection, tearing, nasal congestion, miosis, ptosis, increased forehead 
sweating) 
Q 10. What do you do to relieve the pain? (resting, sitting, walking around) 
Q 11. Is the headache increased by physical activity? (Yes/No) 
Q 12.   Do you have any of the following before, or together with the pain? 
(scintillating scotoma, paresthesia, disturbed sensation, dysphasia) 
Q 13.  If you have any of the symptoms mentioned above; does it come before 
or together with the headache? (before, together with headache)  
Q 14.  If you have any of the symptoms mentioned above; how long do they 
last? (< 5 minutes, 5-15 minutes, 15-30 minutes, 30-45 minutes, 45-60 
minutes, > 60 minutes, varying) 
Q 15. Is the headache triggered by one, or several of the following? 
(stress/anxiety, cheese, chocolate, beer, red wine, spirits, change in 
weather, smell/aromas, relaxation after stress) 
Q 16.  What kind of medication do you use to treat your headache? (no 
medication, acetaminophen, ASA, NSAID, triptans) 
Q 17. How often do you have this headache? (< once a year, 2-3 times/year, 5-6  
times/year, 1 time/month, 2-3 times/month, 1 time/week, 2-3 times/week, 
daily)    
Q 18. Do you still have recurrent headaches? (Yes/No) 
Q 19. If it has ceased; how old were you when it stopped?  
Q 20. Have you had a physician diagnosis of migraine? (Yes/No) 
Q 21. Have you had a physician diagnosis of tension type headache? (Yes/No)  
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8.3 MIGRAINE QUESTIONS USED IN STUDY IV 
8.3.1 SALT 
Q 1.  Have you had recurrent headaches not caused by fever, infection or 
hangover? (Yes/No) 
Q 2. Have you had recurrent headache lasting from 4 hours to 3 days, unless 
you treat them with pain medication? (Yes/No)   
Q 3. Is the pain severity moderate or severe? (Yes/No) 
Q4. Is the headache often unilateral? (Yes/No) 
Q5. Is the headache side-changing between or under an attack? (Yes/No) 
Q 6. Is the headache pounding or pulsatile? (Yes/No) 
Q 7. Is the pain progressing with physical activity? (Yes/No) 
Q 8. Do you feel nauseas or vomit during a headache attack? (Yes/No) 
Q 9. Do you get sensitive for light and/or sound during an attack? (Yes/No) 
Q 10. How old were you when this headache started? (X years) 
Q 11.  Do you get visual disturbances before the start of the headache 
(scintillating scotomas, zigzag-lines)? (Yes/No) 
Q 12. Does the visual disturbances last between 5-60 minutes? (Yes/No) 
 
 
8.3.2 STAGE 
Q 1. Have you had recurrent headaches not caused by fever, infection or 
hangover? (Yes/No) 
Q 2.  Have you had recurrent headaches once a month or more? (Yes/No) 
Q 3. Have you, on at least two occasions, had transient and short-lasting visual 
disturbance (scintillations, zigzag-lines and/or scotoma), which is 
followed by headache? (Yes/No) 
Q 4. Can you sense when a headache is coming? (Yes/No) 
Q 5.  Is the headache severe or very severe? (Yes/No) 
Q 6. Is the headache unilateral? (Yes/No) 
Q 7. Is the headache worsened by physical activity? (Yes/No) 
Q 8. Is the headache pulsating? (Yes/No) 
Q9. Do you often get nauseas when you’re having headaches? (Yes/No) 
Q 10.  Do you often vomit when you’re having headaches? (Yes/No) 
Q 11. Do you get sensitive for light when you’re having headaches? (Yes/No) 
Q 12.  Do you get sensitive for sounds when you’re having headaches? 
(Yes/No) 
Q 13.  Does the headache disrupt your daily activities? (Yes/No) 
Q 14.  Do regular pain killers take the headache away? (Yes/No) 
Q 15. Have you ever consulted a physician because of headache? (Yes/No) 
 
 
 
 
 
 
 52 
8.4  GENETIC POLYMORPHISMS ANALYZED IN STUDY I 
Chr. Gene Name Polymorphism 
      
   
C01 5,10-methylenetetrahydrofolate reductase (MTHFR) ala222val (677 C/T) 
C01 Natriuretic peptide precursor A (NPPA) 2238 T/C 
C01 Natriuretic peptide precursor A (NPPA) 664 G/A 
C01 Coagulation factor V (F5) arg506gln (G/A) 
C01 Selectin E (SELE) leu554phe (C/T) 
C01 Selectin E† (SELE) ser128arg (A/C) 
C01 Renin (REN) C2646T 
C01 Renin (REN) G (-1111) A 
C01 Angiotensin I (AGT) met235thr (T/C) 
C01 Angiotensin I (AGT) A (-6) G 
C01 Angiotensin I (AGT) A (-20) C 
C02 Apolipoprotein B (APOB) E4154K (G/A) 
C02 Apolipoprotein B (APOB) P2712L (C/T) 
C02 Apolipoprotein B† (APOB) thr71ile (C/T) 
C03 
Peroxisome proliferator-activated receptor-gamma 
(PPARG) pro12ala (C/G) 
C03 Angiotensin II receptor, type 1 (AGTR1) G (-535) A 
C03 Angiotensin II receptor, type 1 (AGTR1) T (-153) C 
C03 Angiotensin II receptor, type 1 (AGTR1) 1166 A/C 
C04 Adducin 1; alpha adducin (ADD1) gly460trp (G/T) 
C04 
G protein-coupled receptor kinase GRK4 (GRK4 
(GPRK2L)) R65L (G/T) 
C04 
G protein-coupled receptor kinase GRK4 (GRK4 
(GPRK2L)) A142V (C/T) 
C04 
G protein-coupled receptor kinase GRK4 (GRK4 
(GPRK2L)) A486V (C/T) 
C04 Fibrinogen, beta polypeptide chain (FGB) -455 G/A 
C05 Integrin, alpha-2 (ITGA2) thr246thr (873 G/A) 
C05 Phosphodiesterase 4D (PDE4D) SNP222 (A/G) 
C05 Phosphodiesterase 4D (PDE4D) SNP220 (C/A) 
C05 Phosphodiesterase 4D (PDE4D) SNP219 (C/T) 
C05 Phosphodiesterase 4D (PDE4D) SNP199 (A/G) 
C05 Phosphodiesterase 4D† (PDE4D) SNP175 (C/T) 
C05 Phosphodiesterase 4D (PDE4D) SNP148 (A/G) 
C05 Beta-2-adrenergic receptor (ADRB2) arg16gly (A/G) 
C05 Beta-2-adrenergic receptor (ADRB2) gln27glu (C/G) 
C05 Coagulation factor XII†* (F12) C (-46) T 
C06 Coagulation factor XIII, A1 polypeptide. (F13A1) P564L (C/T) 
C06 Coagulation factor XIII, A1 polypeptide (F13A1) V35L (G/T) 
C06 Lymphotoxin alpha (LTA) thr26asn (C/A) 
C06 Tumor necrosis factor (TNF) -376 G/A 
C06 Tumor necrosis factor (TNF) -308 G/A 
C06 Tumor necrosis factor (TNF) -238 G/A 
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C06 Lipoprotein, Lp (a) (LPA) 121 G/A 
C06 Lipoprotein, Lp(a) (LPA) 93 C/T 
C07 Paraoxonase 1 (PON1) gln192arg (A/G) 
C07 Paraoxonase 1 (PON 1) met55leu (A/T) 
C07 Paraoxonase 1 (PON1) C (-108) T 
C07 Paraoxonase 2* (PON 2) ser311cys (C/G) 
C07 Plasminogen activator inhibitor 1 -675 G5/G4 
C07 Plasminogen activator inhibitor 1(serpine1(PAI1) 11053 G/T 
C07 Nitric oxide synthase 3 (endothelial)(NOS3) -922 A/G 
C07 Nitric oxide synthase 3 (endothelial)(NOS3) -690 C/T 
C07 Nitric oxide synthase 3 (endothelial)(NOS3) glu298asp (G/T) 
C08 Beta-3-adrenergic receptor(ADRB3) trp64arg (T/C) 
C08 Lipoprotein lipase(LPL) -93 T/G 
C08 Lipoprotein lipase (LPL) asp9asn (G/A) 
C08 Lipoprotein lipase (LPL) asn291ser (A/G) 
C08 Lipoprotein lipase (LPL) ser447term (C/G) 
C11 Coagulation factor II or prothrombin (F2) 20210 G/A 
C11 Matrix metalloproteinase 7 (MMP7) C (-153) T 
C11 Matrix metalloproteinase 7 (MMP7) A (-181) G 
C11 Matrix metalloproteinase 1 (MMP1) 1G (-1607)2G 
C11 Matrix metalloproteinase 3 (MMP3)  K45E (A/G) 
C11 Matrix metalloproteinase 3 (MMP3) -1171 A5/A6 
C11 matrix metalloproteinase 12 (MMP12)  N122S (A/G) 
C11 matrix metalloproteinase 12 (MMP12) A (-82) G 
C11 Apolipoprotein A-IV (APOA4) gln360his (G/T) 
C11 Apolipoprotein A-IV (APOA4) thr347ser (A/T) 
C11 Apolipoprotein C-III (APOC3) -641 C/A 
C11 Apolipoprotein C-III (APOC3) -482 C/T 
C11 Apolipoprotein C-III (APOC3) -455 T/C 
C11 Apolipoprotein C-III (APOC3) 1100 C/T 
C11 Apolipoprotein C-III (APOC3) 3175 C/G 
C11 Apolipoprotein C-III (APOC3) 3206 T/G 
C12 Sodium channel, nonvoltage-gated 1 alpha (SCNN1A) ala663thr (G/A) 
C12 Sodium channel, nonvoltage-gated 1 alpha (SCNN1A) trp493arg (T/C) 
C12 Guanine nucleotide-binding protein, beta-3† (GNB 3) 825 C/T 
C13 Coagulation factor VII (F7) G (-402) A 
C13 Coagulation factor VII (F7) G (-401) T 
C13 Coagulation factor VII (F7) -323 10-bp del/ins 
C13 Coagulation factor VII (F7) arg353gln (G/A) 
C15 Lipase, hepatic (LIPC) -480 C/T 
C16 Matrix metalloproteinase 2 (MMP2) C (-1306) T 
C16 Cholesteryl ester transfer protein (CETP) -631 C/A 
C16 Cholesteryl ester transfer protein (CETP) -629 C/A 
C16 Cholesteryl ester transfer protein (CETP) intron 1 Tami +/- (G/A) 
C16 Cholesteryl ester transfer protein* (CETP) ile405val (A/G) 
C16 Cholesteryl ester transfer protein (CETP) asp442gly (A/G) 
C17 Glycoprotein Ib (Platelet), alpha polypeptide† (GP1BA) G (-1691) T 
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C17 Glycoprotein Ib (Platelet), alpha polypeptide (GP1BA) T (-5) C 
C17 Integrin, beta-3 (ITGB3) leu33pro (T/C) 
C17 Angiotensin I converting enzyme (ACE DCP1)) A (-262) T 
C17 Angiotensin I-converting enzyme (ACE DCP1)) intron 16 ins/del 
C17 Angiotensin I converting enzyme (ACE DCP1)) T776T (A/G) 
C17 Angiotensin I converting enzyme (ACE DCP1)) A20320G 
C19 Intercellular adhesion molecule 1 (ICAM 1) gly214arg (G/A) 
C19 Low density lipoprotein receptor (LDLR) NcoI+/- (A/G) 
C19 Apolipoprotein E (APO E) cys112arg (T/C) 
C19 Apolipoprotein E (APO E) arg158cys (C/T) 
C20 Matrix metalloproteinase 9 (MMP9) R279Q (G/A) 
C20 Matrix metalloproteinase 9 (MMP9) R668Q (G/A) 
C20 Matrix metalloproteinase 9 (MMP9) C (+6) T 
C21 Cystathionine beta-synthase (CBS) ile278thr (T/C) 
Markers in Hardy-Weinberg disequilibrium (HWD); *controls, †affected. 
HWD p values were < 0.05. 
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